46TH ANNUAL ESDR MEETING - Home page | ESDR …esdr2016.org/pdf/2016ESDRProgramBook.pdf · TABLE OF...

1

46TH ANNUAL ESDR MEETING

7-10 September 2016Munich, Germany

www.esdr2016.org

INDICATIONOTEZLA is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA).

Introducing

A NOVEL ORAL THERAPY THATMAY CHANGE THE WAY YOUTREAT PSORIASIS

◆ Proven efficacy in clinical trials vs. placebo

◆ Favourable safety profile with no increased risk of malignancy, serious infection, or tuberculosis vs. placebo, demonstrated in clinical trials

◆ Oral dosing

◆ No requirement for tuberculosis prescreening or any ongoing laboratory monitoring

Otezla® 10 mg / 20 mg / 30 mg FilmtablettenWirkstoff: ApremilastZusammensetzung: Jede 10 mg / 20 mg / 30 mg Filmtbl. enth.: 10 mg / 20 mg / 30 mg Apremilast; sonst. Bestandteile: Tablettenkern: mikrokristalline Cellulose, Lactose-Monohydrat, Croscarmellose-Natrium, Magnesiumstearat (Ph.Eur.). Filmüberzug: Poly(vinylalkohol), Titandioxid (E 171), Macrogol 3350, Talkum, Eisen(III)-oxid (E 172). Bei 20 mg zusätzl.: Eisen(III)-hydroxid-oxid x H2O (E 172); bei 30 mg zusätzl.: Eisen(III)-hydroxid-oxid x H2O (E 172), Eisen(II,III)-oxid (E 172).Anwendungsgebiete: Psoriasis-Arthritis: Otezla® allein o. in Komb. mit krankheitsmodifizierenden antirheumat. Arzneimitteln (DMARDs) ist indiziert zur Behandl. der aktiven Psoriasis-Arthritis (PsA) bei erwachsenen Pat., die auf eine vorangegangene DMARD-Therapie unzureichend angesprochen o. diese nicht vertragen haben. Psoriasis: Otezla® ist indiziert zur Behandl. der mittelschweren bis schweren chron. Plaque-Psoriasis bei erwachsenen Pat., die auf eine andere systemische Therapie, wie Ciclosporin

o. Methotrexat o. Psoralen in Komb. mit UVA-Licht (PUVA), nicht angesprochen haben o. bei denen eine solche Therapie kontraindiziert ist o. die diese nicht vertragen haben. Gegenanzeigen: Schwangerschaft; Überempf. gegen d. Wirkstoff o. einen d. sonst. Bestandteile. Nebenwirkungen: Sehr häufig: Diarrhoe, Übelkeit. Häufig: Bronchitis, Infektion d. oberen Atemwege, Nasopharyngitis; Appetitlosigkeit; Schlaflosigkeit; Migräne, Spannungskopfschmerz, Kopfschmerz; Husten; Erbrechen, Dyspepsie, häufiger Stuhlgang, Oberbauchschmerzen, gastroösophageale Refluxkrankheit; Rückenschmerzen; Fatigue. Gelegentlich: Hautausschlag; Gewichtsverlust; allerg. Reaktion; gastrointest. Blutungen. Warnhinweise: Ärztl. Abklärung bei ungeklärtem Gewichtsverlust bei untergewichtigen Pat.. Keine Einnahme bei der seltenen hereditären Galactose-Intoleranz/Lactase-Mangel/Glucose-Galactose-Malabsorption.Vorsichtsmaßnahmen: Anw. starker CYP3A4-Enzyminduktoren wg. mögl. Wirksamkeitsverlust nicht

empfohlen. Dosisredukt. bei stark eingeschr. Nierenfunktion empfohlen. Zuverl. Verhütung bei Frauen im gebärf. Alter; keine Anwendung während der Stillzeit. Weitere wichtige Inf. entnehmen Sie d. Zusammenfassung d. Merkmale des Arzneimittels (Fachinformation).Darreichungsform u. Packungsgröße: Otezla® 10 mg / 20 mg / 30 mg Filmtbl.; Packung mit 27 Filmtbl. (Starterpackung: 4 x 10 mg, 4 x 20 mg, 19 x 30 mg), 56 Filmtbl. (Einmonats-Packung: 56 x 30 mg), 168 Filmtbl. (Dreimonats-Packung: 168 x 30 mg).Verschreibungspflichtig.Pharmaz. Untern.: Celgene Europe Ltd., 1 Longwalk Road, Stockley Park, Uxbridge, UB11 1DB, Vereinigtes Königreich.Stand d. Inf.: Juli 2016

Referenz: Fachinformation Otezla® http://www.ema.europa.eu

TABLE OF CONTENTS

Sponsors of the 46th Annual ESDR Meeting 2016 4Meeting Organisers 4Welcome to Munich 5Complete Daily Program Overview 6Social Program 8SCIENTIFIC PROGRAM BELOW: See pp 6-7 for full program including breaks, ceremonies etc

Wednesday 7 September 2016 ESDR-ADF Joint Symposium 10 2016 Future Leaders Symposium 11 European Epidermal Barrier Research Network (contains Thursday program also) 12 European Society for Pediatric Dermatology EURO-PEDRA Initiative 13 Dermatoendocrinology Symposium 14

European Dermatoepidemiology Network 15 P4 Medicine: Opportunities and Challenges in Psoriasis Treatment 16

Thursday 8 September 2016 Drug Discovery and Translational Medicine 18 Eastern European Research 19 Neurobiology of the Skin 20 Frontiers in Skin Biology & Dermatology 1 21 The LEO Pharma Research Foundation Awards 2016 22 Therapeutic Antibodies: The Evolution Continues 23 Immunological Mechanisms in Health and Disease 24 Plenary Session 1 25 2016 Rudi Cormane Lecture: Carien Niessen 26 Concurrent 1: Epidermal Structure and Function 27 Concurrent 2: Melanoma, Melanocytes and Photobiology 28 Concurrent 3: Adaptive Immunity and Immune Regulation 29

Special Guest Lecture: Thomas Boller 30 Friday 9 September 2016 Intravenous Immunoglobulins in Dermatological Autoimmune Diseases 32 Recent Advances in Acne & Rosacea Research – “Neurogenic inflammation” 33 Skin Aging: How to Overcome Tissue Decline 34 2016 Celgene ESDR Guest Lecture: Brigitta Stockinger 35 Concurrent 4: Genetics and Cell Based Therapy 36 Concurrent 5: Wound Healing and Tissue Remodelling 37 Concurrent 6: Antimicrobial Immunity and Allergic Inflammation 38 Translational Medicine: “Signal Transduction and Disease Pathogenesis” 39 Skin Aging and Pigmentation 40 2016 ESDR Guest Lecture: Gonçalo Abecasis 41 Concurrent 7: Skin Cancer and Epidermal Regulation 42 Concurrent 8: Clinical Outcomes 43 Concurrent 9: Innate Inflammation and Psoriasis 44

2016 René Touraine Guest Lecture: Angela Christiano 45

Saturday 10 September 2016 Frontiers in Skin Biology & Dermatology 2 48 Plenary Session 2 49 2016 EADV Guest Lecture: Eli Sprecher 50 Clinical Saturday Lectures 51 Horizon 2020: EU Funding Opportunities 52

General Information

Poster Information (setup, electronic posters, prizes, poster walks) 54 General and Practical Information 56

INDICATIONOTEZLA is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA).

Introducing

A NOVEL ORAL THERAPY THATMAY CHANGE THE WAY YOUTREAT PSORIASIS

◆ Proven efficacy in clinical trials vs. placebo

◆ Favourable safety profile with no increased risk of malignancy, serious infection, or tuberculosis vs. placebo, demonstrated in clinical trials

◆ Oral dosing

◆ No requirement for tuberculosis prescreening or any ongoing laboratory monitoring

Otezla® 10 mg / 20 mg / 30 mg FilmtablettenWirkstoff: ApremilastZusammensetzung: Jede 10 mg / 20 mg / 30 mg Filmtbl. enth.: 10 mg / 20 mg / 30 mg Apremilast; sonst. Bestandteile: Tablettenkern: mikrokristalline Cellulose, Lactose-Monohydrat, Croscarmellose-Natrium, Magnesiumstearat (Ph.Eur.). Filmüberzug: Poly(vinylalkohol), Titandioxid (E 171), Macrogol 3350, Talkum, Eisen(III)-oxid (E 172). Bei 20 mg zusätzl.: Eisen(III)-hydroxid-oxid x H2O (E 172); bei 30 mg zusätzl.: Eisen(III)-hydroxid-oxid x H2O (E 172), Eisen(II,III)-oxid (E 172).Anwendungsgebiete: Psoriasis-Arthritis: Otezla® allein o. in Komb. mit krankheitsmodifizierenden antirheumat. Arzneimitteln (DMARDs) ist indiziert zur Behandl. der aktiven Psoriasis-Arthritis (PsA) bei erwachsenen Pat., die auf eine vorangegangene DMARD-Therapie unzureichend angesprochen o. diese nicht vertragen haben. Psoriasis: Otezla® ist indiziert zur Behandl. der mittelschweren bis schweren chron. Plaque-Psoriasis bei erwachsenen Pat., die auf eine andere systemische Therapie, wie Ciclosporin

o. Methotrexat o. Psoralen in Komb. mit UVA-Licht (PUVA), nicht angesprochen haben o. bei denen eine solche Therapie kontraindiziert ist o. die diese nicht vertragen haben. Gegenanzeigen: Schwangerschaft; Überempf. gegen d. Wirkstoff o. einen d. sonst. Bestandteile. Nebenwirkungen: Sehr häufig: Diarrhoe, Übelkeit. Häufig: Bronchitis, Infektion d. oberen Atemwege, Nasopharyngitis; Appetitlosigkeit; Schlaflosigkeit; Migräne, Spannungskopfschmerz, Kopfschmerz; Husten; Erbrechen, Dyspepsie, häufiger Stuhlgang, Oberbauchschmerzen, gastroösophageale Refluxkrankheit; Rückenschmerzen; Fatigue. Gelegentlich: Hautausschlag; Gewichtsverlust; allerg. Reaktion; gastrointest. Blutungen. Warnhinweise: Ärztl. Abklärung bei ungeklärtem Gewichtsverlust bei untergewichtigen Pat.. Keine Einnahme bei der seltenen hereditären Galactose-Intoleranz/Lactase-Mangel/Glucose-Galactose-Malabsorption.Vorsichtsmaßnahmen: Anw. starker CYP3A4-Enzyminduktoren wg. mögl. Wirksamkeitsverlust nicht

empfohlen. Dosisredukt. bei stark eingeschr. Nierenfunktion empfohlen. Zuverl. Verhütung bei Frauen im gebärf. Alter; keine Anwendung während der Stillzeit. Weitere wichtige Inf. entnehmen Sie d. Zusammenfassung d. Merkmale des Arzneimittels (Fachinformation).Darreichungsform u. Packungsgröße: Otezla® 10 mg / 20 mg / 30 mg Filmtbl.; Packung mit 27 Filmtbl. (Starterpackung: 4 x 10 mg, 4 x 20 mg, 19 x 30 mg), 56 Filmtbl. (Einmonats-Packung: 56 x 30 mg), 168 Filmtbl. (Dreimonats-Packung: 168 x 30 mg).Verschreibungspflichtig.Pharmaz. Untern.: Celgene Europe Ltd., 1 Longwalk Road, Stockley Park, Uxbridge, UB11 1DB, Vereinigtes Königreich.Stand d. Inf.: Juli 2016

Referenz: Fachinformation Otezla® http://www.ema.europa.eu

4

SPONSORS OF THE 46th ANNUAL ESDR MEETING 2016

Organisation

PLATINUM SPONSOR

GOLD SPONSORS

Sponsors

Local Organising Committee

Tilo Biedermann, Munich (Chair)Johann Bauer, SalzburgMark Berneburg, RegensburgKilian Eyerich, MunichCarien Niessen, CologneJohannes Ring, MunichKarin Scharfetter-Kochanek, UlmCarsten Schmidt-Weber, MunichMatthias Schmuth, InnsbruckClaudia Traidl-Hofmann, AugsburgThomas Volz, MunichFlorian Wölbing, Munich

Scientific Program Committee

David Kelsell (Chair)Jonathan Barker (ESDR President)Salvador Aznar-BenitahTilo BiedermannMichel GillietLionel LarueCaterina MisseroMatthias SchmuthThomas Werfel

Professional Congress OrganiserINTERPLANCongress, Meeting & Event Management AGLandsberger Strasse 155D-80687 Munich, Germany

Tel: +49 89 54 82 34 73Fax: +49 89 54 82 34 43Email: [email protected]://www.interplan.de

European Society for Dermatological Research

Thomas FlorestanExecutive-Director

Caroline Blondel BaldassarreCorporate Development & Membership Coordinator

ESDR7 Rue CingraCH-1205 GenevaSwitzerland

Tel: +41 22 321 48 90 Fax: +41 22 321 48 92Email: [email protected] http://www.esdr.org

CORPORATE PARTNERS PLATINUM SPONSORS

SILVER SPONSORS

5

On behalf of the ESDR Board and program committee I would like to welcome you to the 46th Annual Meeting of the European Society for Dermatological Research in Munich from 7-10 September 2016.

The annual scientific meeting of the ESDR strives to provide a world leading platform for the presentation and discussion of state of the art science as it relates to skin biology and investigative dermatology. The program includes named orations from outstanding globally recognised scientists, plenary educational events such as Frontiers in Skin Biology and Dermatology, workshops, symposia, free communications and posters covering all aspects of skin science extending from genetic discovery through to clinical research.

ESDR is committed to fostering a culture where scientists and clinicians can get together, exchange ideas and form new collaborations in a convivial and stimulating environment. To that end we have encouraged special interest groups to hold satellite meetings at ESDR so that the full breadth of essential expertise is present at the meeting. Recognising the

importance of the translational biomedical research agenda we bring together academia and biopharma and include dedicated sessions discussing many aspects of drug discovery and clinical validation. Our social program is also geared towards creating an environment allowing exchange of ideas and the meeting of old and new friends.

This year in a break with our recent past we will be returning to our academic roots and holding the meeting on an academic campus. Thanks to Tilo Biedermann and the local organising committee we have secured the convenient and fabulous facilities of the Technical University of Munich (Garching campus). Nearby is the Max Planck Institute of Astrophysics and to provide motivation we will have a special lecture on the beginning and end of the Universe!

We look forward to seeing you in Munich!

Jonathan BarkerPresident, ESDR

Welcome from the ESDR President

Dear colleagues and friends,

It is a great pleasure and privilege to welcome you to the 46th Annual Meeting of the European Society for Dermatological Research, held in Munich, Germany from 7-10 September 2016.

Munich, the capital of Bavaria, the third largest city of Germany, is known to have a big heart welcoming its visitors from all over the world. It is a city of science and tradition, of economics, engineering and lifestyle.

As the venue for the ESDR 2016 Meeting we have selected the campus of the TUM (Technical University of Munich) in Garching, which combines a stylish modern architecture with the spirit of an academic environment. The campus in the north of Munich is well connected to the city center by subway U6 and allows

participants to stay in the middle of an exciting city with the best connectivity to the venue site.

Based on the exciting developments in cutaneous biology and skin disease research, the ESDR together with the local organising committee followed the lines of its development and put together a program offering cutting edge science and the best opportunities to interact. We trust that the ESDR in Munich will be both scientifically and personally stimulating, ideal to start new collaborations and make new friends.

We are looking forward to welcome you all in Munich, to spend exciting days with you, and to advance the success story of ESDR meetings.

Tilo BiedermannESDR 2016 Local Organising Committee Chair

Welcome to ESDR 2016

6

Thursday 8 September 2016Program Overview

Wednesday 7 September 2016Program Overview

TIME SESSION LOCATION INFORMATION

13.00-17.00 ESDR-ADF Joint Symposium: “You’ll Never Walk Alone”- Emerging Role of the Cutaneous Microbiome on Skin Diseases

Munich p 10

13.00-18.00 Future Leaders Symposium Copenhagen p 11

13.00-18.00 E2BRN (Part 1) Salzburg p 12

13.00-18.00 ESPD Symposium: EURO-PEDRA Initiative Edinburgh p 13

13.00-18.00 Dermatoendocrinology Symposium Bordeaux p 14

14.00-17.30 EDEN Geneva p 15

14.00-17.30 P4 Medicine: Opportunities and Challenges in Psoriasis Treatment

Rotterdam p 16

18.00-19.00 Satellite Symposia Reception Ground floor, meeting venue p 8

19.00-22.00 Future Leaders Dinner (requires pre-registration)


08.00-10.15 Drug Discovery and Translational Medicine Munich p 18

08.30-10.30 Eastern European Research Rotterdam p 19

08.30-10.30 Neurobiology of the Skin Copenhagen p 20

08.55-10.30 E2BRN (Part 2) Salzburg p 12

10.30-11.00 Coffee Break

11.00-11.15 Opening Ceremony Munich

11.15-12.45 Frontiers in Skin Biology & Dermatology (Frontiers 1) Munich p 21

12.45-14.15 The LEO Pharma Research Foundation Awards 2016 in association with the ESDR

Munich p 22

12.45-14.15 Therapeutic Antibodies: The Evolution Continues Lilly Symposium

Rotterdam p 23

13.15-14.15 Immunological Mechanisms in Health and Disease Janssen Symposium

Salzburg p 24

14.20-15.45 Plenary Session 1 Munich p 25

15.45-16.15 Rudi Cormane Lecture: Carien Niessen (Germany) Munich p 26


17.00-18.30 Concurrent 1: Epidermal Structure and Function Munich p 27

17.00-18.30 Concurrent 2: Melanoma, Melanocytes and Photobiology Salzburg p 28

17.00-18.30 Concurrent 3: Adaptive Immunity and Immune Regulation Rotterdam p 29

18.30-19.00 Special Guest Lecture: Thomas Boller (Germany) Munich p 30

19.00-21.00 Poster Viewing and Welcome Reception p 8

7

Saturday 10 September 2016Program Overview

Friday 9 September 2016Program Overview


08.30-09.30 Intravenous Immunoglobulins in Dermatological Autoimmune Diseases Biotest Symposim

Rotterdam p 32

08.30-09.30 Recent Advances in Acne & Rosacea Research – “Neurogenic inflammation” Galderma Symposium

Salzburg p 33

08.30-09.30 Skin Aging: How to Overcome Tissue DeclineL’Oréal Symposium

Copenhagen p 34

09.30-10.00 Celgene ESDR Guest Lecture: Brigitta Stockinger (UK) Munich p 35

10.00-11.30 Concurrent 4: Genetics and Cell Based Therapy Munich p 36

10.00-11.30 Concurrent 5: Wound Healing and Tissue Remodelling Salzburg p 37

10.00-11.30 Concurrent 6: Antimicrobial Immunity and Allergic Inflammation Rotterdam p 38

11.30-13.00 Coffee Break, Poster Viewing (Odd Numbers), Poster Walks p 55

13.00-14.30 Translational Medicine: “Signal Transduction and Disease Pathogenesis”Celgene Symposium

Rotterdam p 39

13.30-14.30 Skin Aging and Pigmentation Chanel Symposium

Salzburg p 40

14.30-15.00 ESDR Guest Lecture: Gonçalo Abecasis (USA) Munich p 41

15.00-16.30 Concurrent 7: Skin Cancer and Epidermal Regulation Salzburg p 42

15.00-16.30 Concurrent 8: Clinical Outcomes Munich p 43

15.00-16.30 Concurrent 9: Innate Inflammation and Psoriasis Rotterdam p 44


17.00-17.15 Honorary Membership Awards Jens-M Schröder, Giovanna Zambruno

Munich

17.15-17.45 René Touraine Guest Lecture: Angela Christiano (USA) Munich p 45

17.45-18.00 JSID and SID Intersociety Collegiality Awards Munich

18.00-18.45 ESDR Annual General Meeting of Members Munich

19.30-24.00 Social Networking Event Löwenbräukeller p 8


09.00-10.00 Frontiers in Skin Biology & Dermatology (Frontiers 2) Munich p 48

10.00-11.00 Plenary Session 2 Munich p 49

11.00-11.30 2016 EADV Guest Lecture: Eli Sprecher (Israel) Munich p 50

11.30-13.00 Coffee Break, Poster Viewing (Even Numbers), Poster Walks p 55

13.00-14.00 Horizon 2020: Opportunities for Funding Salzburg p 52

13.00-14.30 EADV/ESDR Clinical Saturday Lectures Munich p 51

14.30-15.00 Closing Ceremony and Poster Prizes Munich

8

FRIDAY 9 SEPTEMBER 2016, 19.30-24.00

ESDR 2016 Social Networking Event

Tickets: Can be purchased when you register for the meeting or onsite at the meeting venue. Please purchase your tickets early as places are limited.

Introduction

Join us for a fun and relaxing event on Friday night. This is the perfect occasion to meet with other delegates in an informal environment. Food, beverage and music are included in the ticket price.

The event will be held at the Löwenbräu beer garden and cellars (Löwenbräukeller) in central Munich.

TransportPlease travel by public transport. Details will be provided on-site at the ESDR meeting.

Dress Code: Casual

SOCIAL PROGRAM

WEDNESDAY 7 SEPTEMBER 2016, 18.00-19.00

Satellite Meetings Reception

All attendees of our satellite meetings held on Wednesday 7 September are invited to stay for a short reception at the end of the day. The reception will be held at the ESDR2016 meeting venue around the Poster Areas. A welcome drink will be served.

THURSDAY 8 SEPTEMBER 2016, 19.00-21.00

ESDR 2016 Welcome Reception and Poster Viewing

Included in your registration fee

Our 2016 welcome reception will take place at the ESDR2016 meeting venue around the Poster Areas. This is a great opportunity to meet your colleagues and peers while discussing science. A light food and beverage buffet will be served.

LöwenbräukellerNymphenburger Str. 280335 Munich

9

WEDNESDAY

10

ESDR-ADF Joint Symposium “You’ll Never Walk Alone”- Emerging Role of the Cutaneous Microbiome on Skin DiseasesDate: Wednesday 7 September 2016Time: 13.00-17.00Location: Munich

Chairs: Kilian Eyerich (Munich), Thomas Volz (Munich)

This satellite meeting is open to all registered ESDR 2016 delegates.

The 2016 ESDR-ADF Joint Symposium is supported by La Roche Posay.

PROGRAM

13.00-13.15 Welcome and Introduction Kilian Eyerich (Munich, Germany), Thomas Volz (Munich, Germany)

13.15-14.00 Keynote Lecture The Continuous Expansion of the Skin Microbiome – From Bacteria to Fungi and Back to the Bedside Martin Glatz (Zurich, Switzerland)

14.00-14.12 [Poster 368] Commensal Bacteria Control Plasmacytoid Dendritic Cell Recruitment and Activation in Injured Skin Jeremy di Domizio (Lausanne, Switzerland)

14.12-14.24 [Poster 423] Isotretinoin and Lymecycline Treatments Modify the Skin Microbiota in Acne Hanna-Leena Kelhälä (Oulu, Finland)

14.24-14.36 [Poster 390] Development and Clinical Effect of Novel Probiotic Product for the Skin Containin Staphylococcus Epidermidis Isolated From

Users Itaru Dekio (Tokyo, Japan)

14.36-14.48 [Poster 246] Prebiotic Stimulation of Innate Immune System, Skin Barrier and Staphylococci-homeostasis Sabrina Leoty-Okombi (Lyon, France)

14.48-15.00 [Poster 116] Probiotic Regulation of ABCA1 and Cholesterol Efflux in Primary Human Keratinocytes Iain Haslam (Huddersfield, UK)


15.30-16.15 Keynote Lecture The Skin Microbiome in Atopic Dermatitis Patients - Pathophysiological Insights and Therapeutic Approaches Thomas Volz (Munich, Germany)

16.15-16.27 [Poster 438] Differences Between the Microbiome of Lesional and Non-lesional Skin in Atopic Dermatitis Matthias Reiger (Munich, Germany)

16.27-16.39 [Poster 288] Staphylococcal Lipoteichoic Acid Suppresses T Cell Function in vitro and in vivo Yuliya Skabytska (Munich, Germany)

16.39-16.51 [Poster 369] Development of an in vitro Follicle Model to Study the Interaction of Kerationcytes, Sebocytes and Propionibacterium Acnes Katalin Glasenhardt (Szeged, Hungary)

16.51-17.03 [Poster 350] Anti-inflammatory Role of TNIP1 in the Propionibacterium Acnes-induced Signaling Events in Human Epidermal Keratinocytes Lilla Erdei (Szeged, Hungary)

17.03 Concluding Remarks

18.00-19.00 Satellite Meetings Reception

11

2016 Future Leaders SymposiumWomen in Science: Towards Gender EqualityDate: Wednesday 7 September 2016Time: 13.00-18.00Room: Copenhagen

Goal: to facilitate interaction and collaboration between young ambitious researchers and current leaders in the field of investigative dermatology around the world.

Program Organizing Committee ESDR: Ellen Van Den Bogaard, Matthew Caley, Christina Zielinski, Kilian Eyerich JSID: Masatoshi Jinnin, Hayato Takahashi SID: Christian Posch, Tobias Schatton

The Future Leaders Symposium is open to all ESDR 2016 delegates. Places at the Future Leaders dinner are limited and pre-registration is required.

The 2016 Future Leaders Symposium is supported by:

PROGRAM

12.30-13.00 Registration

13.00-13.20 Welcome and introduction to Future Leaders Symposium

ESDR: Ellen van den Bogaard JSID: Hayato Takahashi SID: Christian Posch

Session 1 Chairs: Christian Posch and Ellen Van Den Bogaard

13.20-13.50 Keynote speaker from the ESDR The Path from MD/PhD to Clinician Scientist in

Dermatology Leena Bruckner-Tudermann (Freiburg, Germany)

13.50-14.50 Scientific Presentations (15min + 3 min questions)

ESDR Latrogenic ‘Genodermatoses’ Induced by Targeted

Therapy Lise Boussemart (Villejuif, France)

JSID The Role of Basement Membrane Proteins in

Regulating Epidermal Homeostasis Mika Watanabe (Hokkaido, Japan)

SID The Role of Host Skin T cells in GVHD Sherrie J. Divito (Boston, USA)

14.50-15.30 Interactive session led by Matthew Caley

In vivo Imaging in Skin Inflammation Jennifer Kloepper (Lübeck, Germany) Stratified Medicine in Psoriasis (an Omics Approach) Amy Foulkes (Manchester, UK)

Genetic Polymorphisms in Skin Cancer Mary Laing (Galway, Ireland) Psoriasis and Melanoma: A Controversial Relationship Anna Balato (Rome, Italy) How to Define T Helper Cell Subsets Christoph Schlapbach (Bern, Switzerland)

15.30-15.50 Special Guest Lecture: Meet and Greet with JID Editor Barbara Gilchrest (Boston, USA)


Session 2 Chairs: Matthew Caley and Masatoshi Jinnin

16.10-16.40 Keynote speaker from the JSID Seek What you Want to Do and Stick to What you are

Interested in Chikako Nishigori (Kobe)

16.40-17.10 Keynote speaker from the SID If Opportunity Doesn’t Knock, Build a Door Angela Christiano (New York, USA)

17.10-17.40 Discussion panel led by Christina Zielinski (Munich) Questions from the audience on career making, work-

life balance, grants, moving labs etc. Chikako Nishigori, Claudia Traidl-Hoffmann, Ellen van

den Bogaard, Leena Bruckner-Tudermann, Angela Christiano

17.40-17.45 Closing Remarks


19.00 Future Leaders Dinner (for pre-registered delegates)

12

14th meeting of the European Epidermal Barrier Research Network (E2BRN)Date: Wednesday 7 September 2016, Thursday 8 September 2016Room: Salzburg


PROGRAM

Wednesday 7 September 2016

13.00-13.05 Opening remarks Johanna Brandner (Hamburg, Germany)

Session 1. The skin barrier: Molecular mechanisms in health and disease Chairs: Reiko Tanaka (London, UK) & Giel Tanghe (Gent, Belgium)

13.05-13.30 Multiple functions of AKT1 in epidermal barrier function and disease Ryan O’Shaugnessy (London, UK)

13.30-13.55 Nuclear receptors in skin homeostasis and disease Paloma Perez (Valencia, Spain)

13.55-14.10 Mice humanized for PXR in the epidermis exhibit a skin barrier defect associated with a Th2/Th17 immune response, resembling atopic dermatitis

Andreas Elentner (Innsbruck, Austria)

14.10-14.25 PepFect6-miRNA-146a nanocomplexes inhibit inflammatory responses and reduce changes in the epithelial barrier in a mouse model of irritant contact dermatitis

Egon Urgard (Tartu, Estonia)

14.25-14.40 A role for connexin mediated signalling in the pathogenesis of psoriasis Erin M O´Shaughnessy (Glasgow, UK)

14.40-16.00 Coffee Break and Poster Session

Session 2. The skin barrier: Locking out or letting in? Chairs: Paloma Perez (Valencia, Spain) & TBA (young scientist)

16.00-16.25 The keratin scaffold in the epidermis Thomas Magin (Leipzig, Germany)

16.25-16.50 Challenges and opportunities in topical delivery Sandra Simoes (Lisbon, Portugal)

16.50-17.05 Epidermal tight junctions are strengthened by short-term Staphylococcal challenge in an agr dependent manner Katja Bäsler (Hamburg, Germany)

17.05-17.20 Through deimination, low environmental humidity drives human filaggrin breakdown Laura Cau (Toulouse, France)

17.20-17.35 Sphingomyelin concentrates into lipid microdomains only in non-senescent cells and enhances keratinocyte migration Abdallah Mound (Namur, Belgium)

17.35-17.50 Poster Prizes announcement


Thursday 8 September 2016

Session 3. Shaping the epidermis Chairs: Wim Declercq (Gent, Belgium) & Barbora Skolova (Czech Republic)

08.55-09.20 Cell shape determines the regulatory mechanisms for epidermal turnover Akiharu Kubo (Tokyo, Japan)

09.20-09.45 Corneocyte alterations in AD Sanja Kezic (Amsterdam, The Netherlands)

09.45-10.00 Epidermal equivalents of filaggrin null keratinocytes do not show impaired skin barrier function Hanna Niehues (Nijmegen, The Netherlands)

10.00-10.15 mTORC1 signalling serves as a switch between keratinocyte proliferation and differentiation and thereby contributes to epidermal stratification

Claudia Buerger (Frankfurt, Germany)

10.15-10.30 Reconstructed human skin from aged fibroblasts emulates aspects of physiological skin aging Christian Hausmann (Berlin, Germany)

13

European Society for Pediatric Dermatology EURO-PEDRA InitiativeDate: Wednesday 7 September 2016Time: 13.00-18.00Location: Edinburgh

For a more scientific focus of the ESPD’s activities in the field of pediatric dermatology, the EURO-PEDRA Initiative has been finally established. The main goal of the Pediatric Dermatology Research Alliance on the European level (EURO-PEDRA) is to create long-term collaborative research network that would perform clinical trials and act as an access point for knowledge sharing in innovative therapeutics, biomedicals and medical devices. This Initiative should thus stimulate the attention of the non-pediatric dermatological community to encourage research in the field of pediatric dermatology.


PROGRAM

13.00 Introduction: In memory of Peter de Merlier Daniel Hohl (Switzerland)

13.00-13.15 New insights in barrier structure in atopic dermatitis Regina Fölster-Holst (Germany)

13.15-13.30 Clinical studies with targeted strategies for atopic dermatitis Andreas Wollenberg (Germany)

13.30-13.45 Genetic studies in children Veronica Kinsler (UK)

13.45-14.00 Expanding clinical and molecular spectrum of phacomatosis pigmentokeratotica Fanny Morice-Picard (France)

14.00-14.15 Preliminary safety results from the French cohort of phase 2a trial of sirolimus in PIK3CA-related overgrowth - the PROMISE study

Pierre Vabres (France)

14.15-14.30 Disseminated Juvenile Xanthogranuloma - Clinical, Diagnostic and Therapeutic Aspects in 9 Children Kathrin Giehl (Germany)

14.30-14.45 Follow up of treatment possibilities and side effects of hemangiomas and vascular malformations in pediatric age Zsuzsanna Szalai (Hungary)

14.45-15.00 Scoring infantile haemangiomas: the Haemangioma Activity Score Sherief Janmohamed (Belgium)

15.00-15.15 Improved understanding of infant skin physiology, maturation and skin care Ulrike Blume-Peytavi (Germany)

15.15-16.00 Coffee Break & Poster Viewing

1) Identification of a Novel Mutation in RIPK4 in a Kindred with Phenotypic Features of Both Bartsocas-Papas and CHAND Syndrome

Benjamin Gollasch, F. Buket Basmanav, Arti Nanda, Günter Fritz, Holger Thiele, Janine Altmüller, Peter Nürnberg, Jorge Frank, Regina C. Betz*

2) Low 25-Hydroxyvitamin D Levels in Vitiligo. Case report Sandra Jerkovic Gulin*, Anca E. Chiriac, Liliana Foia, Anca Chiriac 3) Focal Facial Dermal Dysplasia Type 4: Identification of Novel CYP26C1 Mutations In Unrelated Patients Fanny Morice-Picard*, Beom Hee Lee, Anne-Sophie Dutkiewicz, Alain Taïeb, Franck Boralevi, Robert J. Desnick 4) Endothelial dysfunction in patients with moderate and severe psoriasis without classic cardiovascular predictors Karolína Vorčáková*, Klára Martinásková, Lenka Turočová 5) Type II segmental PTEN Hamartoma Syndrome (SOLAMEN Syndrome) in a 1.5 year old girl Alexandra Walter*, Beate Häberle, Winfried Lipp, Orsolya Genzel-Boroviczeny, Heinrich Schmidt, Luana Niculescu, Rudolf Happle,

Dennis Döcker, Kathrin Giehl

16.00-16.30 Keynote lecture: Where stands the PEDRA: The American experience Amy Paller (USA)

16.30-17.00 Keynote lecture: Where stands the ERN-Skin project: The European experience Christine Bodemer (France)

17.00-18.00 Round-table discussion: What are the challenges for the EURO-PEDRA? Daniel Hohl, Regina Fölster-Holst, Christine Bodemer, Stéphanie Christen-Zäch, Arnold Oranje


14

4th Dermatoendocrinology Symposium Date: Wednesday 7 September 2016Time: 13.00-18.00Room: Bordeaux

Organizers: Markus Böhm (Münster, Germany) & Ralf Paus (Manchester, UK, & Münster, Germany)

This symposium is open to all registered ESDR 2016 delegates.

PROGRAM

13.00-13.10 Welcome & Introduction Thomas Luger (Münster, Germany)

13.10-13.40 Lecture 1: Hormonal control of epidermal melanin pigmentation (20 min + 10 min discussion) Juan-Carlos Garcia-Borron (Murcia, Spain)

13.40-14.10 Lecture 2: Alpha-AchR – An emerging target for the development of dermatoendocrinogical therapy (20 min + 10 min discussion) Markus Böhm (Münster, Germany)

14.10-14.25 The potential role of vitamin D in skin stress response (10 min + 5 min discussion) Justyna Marta Wierzbicka (Gdansk, Poland)

14.25-14.40 Human hair follicle can “smell”: OR2AT4-mediated hair growth regulation (10 min + 5 min discussion) Jérémy Chéret (Münster, Germany & Brest, France)

14.40-15.10 Lecture 3: Neuroendocrine controls of keratin experession – Concepts and potential translational relevance (20 min + 10 min discussion)

Yuval Ramot (Jerusalem, Israel)


15.40-16.10 Lecture 4: A genetic perspective on how androgens and other hormones may impact on androgenetic alopecia (20 min + 10 min discussion)

Stefanie Heilmann-Heimbach (Bonn, Germany)

16.10-16.25 The neuropeptide melanin concentrating hormone contributes to psoriasis by modulating skin inflammation and proliferation via MCH receptor 1 (10 min + 5 min discussion)

Gang Wang (Xi‘an, China)

16.25-16.40 Growth hormone-induced signaling: A novel, intrafollicular neuro-endocrine control of human hair growth (10 min + 5 min discussion)

Majid Alam (Münster, Germany)

16.40-17.10 Lecture 5: Immune regulation by α-MSH and related peptides (20 min +10 min discussion) Karin Loser (Münster, Germany)

17.10-17.40 Lecture 6: A cardiovascular research perspective on dermatoendocrinology: Angiotensin and angiotensin receptors as forgotten regulators of skin physiology (20 min + 10 min discussion)

Ulrike Steckelings (Odense, Denmark)

17.40-18.00 Final Discussion & Closing Remarks Thomas Luger, Ralf Paus, Markus Böhm


NOTES.............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................

15

European Dermato-Epidemiology Network (EDEN)Harmonising Dermatology Outcome Measures: Quo Vadem?Date: Wednesday 7 September 2016Time: 14.00-17.30Location: Geneva

Chairs: Carsten Flohr (London, UK) and Phyllis Spuls (Amsterdam, The Netherlands)


PROGRAM

14.00-14.05 Welcome and Introduction Carsten Flohr (London, UK)

14.05-14.30 Keynote Lecture Heterogeneity in Outcomes in Dermatology Research: How Can we Reduce Research Waste? Phyllis Spuls (Amsterdam, The Netherlands)

14.30-14.45 OA01 [Poster 018] Impact of Biologic Therapies on the Quality of Life of Psoriasis Patients: Results from the British Association of Dermatologists’ Biologic Interventions Register

Ireny Iskandar (Manchester, UK)

14.45-15.00 OA02 [Poster 047] Validation of the Self-Assessment Vitiligo Extent Score (SA-VES) as a Patient Reported Outcome Reinhart Speeckaert (Ghent, Belgium)

15.00-15.15 OA03 [Poster 016] The Impact of Interventions on Quality of Life in Psoriasis and the Concept of Multiple Minimal Clinically Important Difference (MCID): a systematic review

Faraz Ali (Cardiff, UK)


15.45-16.00 OA04 [Poster 023] Efficacy and Tolerability of Biologic Therapies for Psoriasis: Network Meta-Analysis Zarif Jabbar-Lopez (Newcastle, UK)

16.00-16.15 OA05 [Poster 516] Effect of UV-A on Pruritus During UVA/B-phototherapy of Inflammatory Skin Diseases - a Randomized Double Blind Study

Julia Maul (Zurich, Switzerland)

16.15-16.30 OA06 [Poster 335] Use of the Hurley Staging System for the Assessment of Hidradenitis Suppurativa Disease Severity in 2 Phase 3 Clinical Trials

Henrique Teixeira (Chicago, USA)

16.30-17.00 Keynote Lecture HISTORIC – The Hidradenitis SuppuraTiva cORe Outcomes Set International Collaboration John Ingram (Cardiff, UK)


NOTES.............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................

16

P4 Medicine: Opportunities and Challenges in Psoriasis Treatment Date: Wednesday 7 September 2016Time: 14.00-17.30Room: Rotterdam

Chairs: Chris Griffiths (Manchester, UK), Catherine Smith (London, UK)


PROGRAM

14.00-14.10 Welcome and Introduction Chris Griffiths (Manchester, UK)

14.10-14.35 Predictive: Predicting Disease Progression Richard Warren (Manchester, UK)

14.35-15.00 Preventative: Preventing Comorbidities such as Psoriatic Arthritis and Cardiovascular Disease Brian Kirby (Dublin, Ireland)

15.00-15.25 Personalized: Psoriasis Stratification to Optimize Relevant Therapy (PSORT) Consortium Nick Reynolds (Newcastle, UK)

15.35-15.45 Break

15.45-16.10 Participatory: Biobanking Resources and Patient Networks for Psoriasis Matthias Augustin (Hamburg, Germany)

16.10-16.35 An Industry Perspective of P4 Medicine Deepak Rajpal (King of Prussia, PA, USA)

16.35-17.00 P4 Medicine in Autoimmune and Inflammatory Diseases Ian Bruce (Manchester, UK)

17.00-17.15 Audience Q & A Catherine Smith (London, UK)

17.15-17.30 Conclusions and adjournment


NOTES............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................

17

THURSDAY

18

Drug Discovery and Translational MedicineTherapeutic Monoclonal Antibodies in Dermatology: From Discovery to ClinicDate: Thursday 8 September 2016Time: 08.00-10.15Room: Munich

Chairs: Jonathan Barker, Michel Gilliet

This educational ESDR session is supported by a grant from:

PROGRAM

08.00-08.25 Target Validation and Therapeutic Antibody Development and Production Brian Nickoloff (Lilly), 20 minutes plus 5 minutes discussion

08.25-08.50 Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Factors to Consider Ajay Nirula (Lilly), 20 minutes plus 5 minutes discussion

08.50-09.50 Science behind Therapeutic Antibody use in Dermatology:

i) Psoriasis Curdin Conrad (Lausanne), 15 minutes plus 5 minutes discussion

ii) Atopic Dermatitis Bernhard Homey (Düsseldorf), 15 minutes plus 5 minutes discussion

iii) Melanoma Dirk Schadendorf (Essen), 15 minutes plus 5 minutes discussion

09.50-10.15 Factors to Consider in Health Economic Evaluation of Therapeutic Antibodies in Dermatology Katherine Payne (Manchester), 20 minutes plus 5 minutes discussion

NOTES............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................

19

Eastern European Research SymposiumDate: Thursday 10 September 2015Time: 08.30-10.30Room: Rotterdam

Chairs: Zsuzsanna Bata-Csörgo (Szeged, Hungary), Johann Bauer (Salzburg, Austria)

PROGRAM

08.30-08.35 Welcome and Introduction Zsuzsanna Bata-Csörgo (Szeged, Hungary)

08.35-08.55 Keynote Lecture

Transglutaminase Pathology in Skin Diseases Sarolta Kárpati (Budapest, Hungary)

08.55-09.05 Sebocytes Differentially Express and Secrete Adipokines Dóra Kovács (Debrecen, Hungary)

09.05-09.15 Abnormal Regulation of Fibronectin Production by Fibroblasts in Psoriasis Barbara Gubán (Szeged, Hungary)

09.15-09.25 Oral Lichen Planus With Severe Nail Involvement in a 10-year Old Boy Magda Zychowska (Wroclaw, Poland)

09.25-09.35 Valuation of Pemphigus Vulgaris and Foliaceus Health States: A Convenience Sample Experiment Fanni Rencz (Budapest, Hungary)

09.35-09.45 The TRPA1 Ion Channel Mediates Inhibitory Effects on Imiquimod-induced Psoriasiform Skin Inflammation Agnes Kemény (Pécs, Hungary)

09.45-09.55 The Association Between Early-onset and Late-onset Psoriasis and Co-morbidities in a Case-control Study Eszter Anna Janka (Debrecen, Hungary)

09.55-10.05 FRA1 as the Regulator of Psoriasis-associated Hyperproliferation and EMT transition of Keratinocytes Alena Zolotarenko (Moscow, Russia)

10.05-10.15 MCPIP1 Endoribonuclease Mediates Proliferation and Differentiation of Human Epidermal Keratinocytes Piotr Konieczny (Krakow, Poland)

10.15-10.25 MiR-10a Controls the Proliferation and Inflammatory Responses of Human Primary Keratinocytes Toomas Runnel (Tartu, Estonia)

10.25-10.30 2016 EER Awards

About the EER Awards

The European Society of Dermatological Research and the Austrian Society of Dermatology are jointly engaged in fostering dermatological research in Eastern Europe. Together they sponsor awards to provide recognition to young and established academic dermatologists in this area.

20

Neurobiology of the Skin Date: Thursday 8 September 2016Time: 08.30-10.30Room: Copenhagen

Chairs: Anna Zalewska (Lodz, Poland) & Marcus Maurer (Berlin, Germany)

PROGRAM

08.30-08.33 Welcome and Introduction Anna Zalewska (Lodz, Poland)

08.33-08.49 Tachykinergic Mechanisms in Atopic Dermatitis Louise Lönndahl, Klas Nordlind (Stockholm, Sweden)

08.49-09.05 Olfaction and Hair Growth Ralf Paus (Manchester, UK) 09.05-09.21 Molecular Mechanisms of Pruritus: Also Innate Immune System Itches Martin Steinhoff (Dublin, Ireland)

09.21-09.37 Clinical Aspects of Pruritus in Healthy and Diseased Skin Martin Metz (Berlin, Germany)

09.37-09.53 New Findings on Disturbed Cutaneous Neurophysiological Function in Chronic Pruritus Konstantin Agelopoulos, Sonja Ständer (Münster, Germany)

09.53-10.09 Neuro-cutaneous Synapses Laurent Misery (Brest, France)

10.09-10.25 How to Minimize or Maximize Placebo Effects in Research and Clinical Practice? Andrea W.M. Evers (Leiden, The Netherlands)

10.25-10.30 Closing Remarks Marcus Maurer (Berlin, Germany)

NOTES............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................

21

Frontiers in Skin Biology & Dermatology 1Date: Thursday 8 September 2016Time: 11.15-12.45Room: MunichChairs: Salvador Aznar-Benitah, Christina Zielinski

Introduction

Dermatology has numerous interfaces with basic science fields. Thus, a constant update in these areas is crucial for the further development of dermatological research. The purpose of the Frontiers in Skin Biology and Dermatology lectures is to provide overviews about about emerging fields in science including non-dermatological topics that are relevant for experimental and clinical dermatology. These talks are principally intended as essential updates for “non-experts”. The Frontiers lectures are likely to be two of the most popular sessions at the 2016 ESDR meeting.

This ESDR educational session is supported by a grant from:

PROGRAM

11.15-11.45 Epidermal Stem Cells Mutation and Cancer Phil H Jones (Cambridge, UK)

11.45-12.15 Modeling Cancer in Organoids Marc Van de Wetering (Utrecht, The Netherlands)

12.15-12.45 Immunological Checkpoints and Cancer Therapy Pedro Romero (Lausanne, Switzerland)

FACULTY

Phil H Jones His research focuses on how tumours evolve from individual mutant stem cells. The focus is on the skin epidermis and oesophagus,

using large scale genetic lineage tracing in transgenic models to quantify how mutation alters normal stem cell behaviour. His group has recently discovered that loss of Notch signalling, a frequent event in human cancer, results in the mutant stem cells becoming ‘super competitors’ that drive out their wild type neighbours and colonise large areas of tissue. Mutation of the TP53 gene also gives mutant cells a competitive advantage. These findings in model systems help to explain the high burden of large mutant clones in normal human sun exposed skin, where Notch and TP53 mutations emerge as two drivers of clonal expansion. Both these mutations tilt the normally balanced fate of stem cells towards producing an excess of proliferating over differentiating daughters.

His current work develops these themes and uses live imaging and single cell analysis to link cell fate with molecular changes in normal and mutant primary human cells in culture. He is also extending studies in mapping clones of cells carrying cancer driver mutations in normal human epithelia, both to provide a personalised cancer risk assay in carcinogen exposed subjects and to understand the range of genes that regulate cell fate in humans.

Marc Van de Wetering Dr Marc van de Wetering is a senior researcher at the Princess Maxima Center for Pediatric Oncology. His research focusses on stem

cells in development, homeostasis and disease. He has strong expertise in organoid technology and is currently exploring the use of patient derived brain organoids for cancer research and precision medication.

Pedro Romero It is now well established that cancer patients may acquire tumor specific T- and B-cell immunity. Various types of human tumor

cells often express multiple CTL-defined tumor antigens that are shared among tumors, providing the rationale for generic vaccines applicable to large subsets of cancer patients. Prof Romero’s main interests are in understanding the dynamics of tumor antigen-specific T cell responses and applying this knowledge to the design of peptide-based therapeutic vaccines.

22

The LEO Pharma Research Foundation Awards 2016Date: Thursday 8 September 2016Time: 12.45-14.15Room: Munich

Introduction

LEO Pharma Research Foundation was established in 1947 by LEO Pharma’s owner at that time, manufacturer Knud Abildgaard, in memory of the founder of the company, pharmacist August Kongsted. The LEO Pharma Research Foundation (previously called ”Løvens Kemiske Fabriks Forskningsfond”) has supported research within medicine, chemistry, biology and pharmacy throughout the years.

In 2008, LEO Pharma Research Foundation established two new awards. Once a year, a Gold Award (DKK 1,000,000) and a Silver Award (DKK 500,000) are given to talented and committed young researchers in recognition of their exceptional contribution to science. The selection of candidates is made in association with the European Society for Dermatological Research (ESDR). ESDR administers the advertising and all applications are reviewed by nominated members of the ESDR Scientific Committee, who submit a shortlist of the strongest candidates. The final selection of the Gold and Silver Award winners is made by the LEO Pharma Research Foundation’s Award Committee.

The LEO Pharma Research Foundation is independent from the LEO Foundation as well as the rest of LEO Pharma and has its own board.


PROGRAM

12.45-12.50 Introduction to the Award Ceremony Thorsten Thormann, Chairman of LEO Pharma Research Foundation Award Committee

12.50-13.00 Introduction to the Award Winners and Presentation of the Awards Jonathan Barker, President of the ESDR

13.00-13.25 Gold Award Lecture Dissecting the Contribution of Ultraviolet Radiation to Melanoma Amaya Virós (Manchester, UK)

13.25-13.50 Silver Award Lecture Understanding and Taming Cancer – Implementing Tumor Genomics Into Clinical Practice Thomas Wiesner (Vienna, Austria)

13.50-14.15 Keynote Lecture Crosstalk Among p53 Family Members in Cutaneous Carcinoma Caterina Missero (Naples, Italy)

This symposium is supported by LEO Pharma Research Foundation.

NOTES............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................

23

Therapeutic Antibodies: The Evolution Continues Date: Thursday 8 September 2016Time: 12.45-14.15Room: Rotterdam


PROGRAM

12.45-12.50 Welcome Ulrich Mrowietz (Kiel, Germany)

12.50-13.15 Therapeutic Antibodies for Psoriasis: Grandfather-Father-Son and the Next Generation Ulrich Mrowietz (Kiel, Germany)

13.15-13.40 Anti-IL17 and the Future Brian Nickoloff (Indianapolis, USA)

13.40-14.05 Immunology meets Practice Denis Jullien (Lyon, France)

14.05-14.15 Discussion and Wrap-Up Ulrich Mrowietz (Kiel, Germany)

NOTES............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................

24

Immunological Mechanisms in Health and Disease Date: Thursday 8 September 2016Time: 13.15-14.15Room: Salzburg

Chairs: Thomas Werfel (Hannover, Germany)


PROGRAM

13.15-13.35 Generation of Tissue-resident T cells by Nanoparticle Formulations Georg Stary (Vienna, Austria)

13.35-13.55 Neutrophil Skin Inflammation in Immunity and Disease Christoph Schlapbach (Bern, Switzerland)

13.55-14.15 Immune Deviations in Atopic Dermatitis Thomas Werfel (Hannover, Germany)

NOTES............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................

25

Plenary Session 1 Date: Thursday 8 September 2016Time: 14.20-15.45Room: Munich

Chairs: Jonathan Barker, Akimichi Morita, Alice Pentland

The duration of each plenary talk is 8 minutes plus 2 minutes discussion.

14.20-14.30 Oral 001 [Poster 126] iRHOM2 regulates Keratin 16, a Major Cytoskeletal Stress Keratin A Chikh, T Maruthappu and DP Kelsell Cell Biology and Cutaneous Research, Blizard Institute, Barts and The London School of

Medicine and Dentistry, London, United Kingdom

14.30-14.40 Oral 002 [Poster 485] Mutations in ACTRT1 and its Transcribed Non-coding Elements Lead to Aberrant Activation of the Hedgehog Signaling Pathway in

Inherited and Sporadic Basal Cell Carcinomas E Bal1 , Z Belaid-Choucair,1 H Kayserili,2 M Madrange,1 H Park,3 E Chiticariu,3 T Magnaldo,4 D Hohl,3 A Munnich1 and A Smahi1

1INSERM U1163 - Institut Imagine, Paris, France, 2Medical Genetics Department, Istanbul Medical Faculty, Istanbul, Turkey, 3Lausanne University Hospital, Lausanne, Switzerland and 4Centre Hospitalier Universitaire, Hôpital du Bocage, Dijon, France

14.40-14.50 Oral 003 [Poster 078] Altered Granular Layer Structure and Enhanced Percutaneous Immune Responses in Keratinocyte Proline-rich Protein-deficient

Mice, A New Mouse Model for Atopic Dermatitis Y Sato1, M Sugaya,2 H Suga,2 T Oka,2 T Ishii,1 H Nishida,1 S Ishikawa,3 M Fukayama3 and S Sato2 1Research and Development, ROHTO

Pharmaceutical Co., Ltd., Osaka, Japan, 2Dermatology, Univ. of Tokyo, Tokyo, Japan and 3Pathology, Univ. of Tokyo, Tokyo, Japan

14.50-15.00 Oral 004 [Poster 232] NOD2 Signaling Critically Influences Sensitization to Orally Ingested Allergens and Severity of Anaphylaxis T Volz, F Wölbing, F Regler, S Kaesler and T Biedermann Department of Dermatology and Allergology, Technical University Munich,

Munich, Germany

15.00-15.10 Oral 005 [Poster 511] Interferon-dependent Senescence is Necessary for Cancer Control during Immunotherapy E Brenner1, BF Schörg,2 T Wieder,1 H Braumüller,1 J Bauer,1 K Ghoreschi,1 A Yazdi,1 B Pichler2 M Kneilling2 and M Röcken1

1Dermatology, Eberhard Karls University, Tübingen, Germany and 2Preclinical Imaging and Radiopharmacy, Eberhard Karls University, Tübingen, Germany

15.10-15.20 Oral 006 [Poster 572] Resident Progenitors of Endothelial Origin Contribute to Neo-vessel Formation through the Expression of Sox18 during Skin

Wound Healing J Patel, M Francois and K Khosrotehrani The University of Queensland, Brisbane, QLD, Australia

15.20-15.30 Oral 007 [Poster 396] Vc1+T-cells are Stress-sentinels in Human Skin and are Implicated in Alopecia Areata Pathogenesis Y Uchida,1 J Gherardini,1 M Alam,2 A Keren,3 A Arakawa,4 A Rossi5 A Gilhar3 T Kanekura6 M Bertoli1 and R Paus7 1University of

Münster, Germany,2 Monasterium Laboratory, Münster, Germany, 3Technion-Israel Institute of Technology, Haifa, Israel, 4University of Munich, Germany, 5University “La Sapienza”, Rome, Italy, 6Kagoshima University, Kagoshima, Japan and 7University of Manchester, United Kingdom

15.30-15.40 Oral 008 [Poster 098] Chromatin Architectural Protein CTCF Controls Keratinocyte Differentiation, Barrier Maintenance and Suppresses Inflammation

and Tumorigenesis in the Epidermis I Malashchuk, J Rudolf, K Poterlowicz, M Fessing, AN Mardaryev and V Botchkarev Centre for Skin Sciences, University of Bradford,

Bradford, United Kingdom

26

2016 Rudi Cormane LectureSticking and Polarization: Necessary Tools to Build and Maintain the Skin BarrierDate: Thursday 8 September 2016Time: 15.45-16.15Room: Munich

Introduced by: Matthias Schmuth

About the Rudi Cormane LectureThe Rudi Cormane Lecture is ESDR’s most prestigious lecture. It is given by an internationally recognised individual who has made a significant contribution to the ESDR and who has carried out high quality science relevant to dermatology. Prof Rudi Cormane (1925-1987) was a founding member of the ESDR as well as serving as its Treasurer and President.

Carien Niessen, PhD Group Leader, Niessen Lab, University of Cologne at the CECAD Research Center, GermanyCologne, Germany

Research Profile

The skin barrier protects organisms from drying out and is the first line of defense against micro-organisms, UV radiation and heat. To maintain and restore the skin barrier, the interfollicular epidermis and its appendages must continously be renewed. Different populations of stem- and progenitor cells guarantee constant self-renewal under steady state conditions and sufficient plasticity for the fast replacement of lost tissue in case of injury. The overall goal of the Niessen laboratory is to understand how regulators of cell structure integrate with regulators of metabolic activity, proliferation and inflammation to control skin barrier formation and homeostasis.

Overall, the focus is on three main research questions:

How do cell adhesion and polarity pathways regulate barrier formation, self-renewal and homeostasis in a stratified epithelium?

How do cell adhesion and polarity pathways couple to signal transduction pathways to regulate stem cell behavior, barrier function and tissue homeostasis?

How do age-associated alterations in molecular regulators of cell architecture alter progenitor cell behavior and result in impairment of the skin barrier?

To address these questions they have chosen mouse epidermis as one in vivo model system. In this self-renewing tissue, cells derived from the basal layer continuously rearrange and move into suprabasal layers while undergoing differentiation. Ultimately, this differentiation process results in the formation of the largest physical barrier of the organism. Formation and maintenance of this barrier is not only crucial for skin homeostasis but also directly affect the function of other organs. Several stem/progenitor cell populations have been described that maintain turnover of epidermal compartments.

NOTES............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................

27

Concurrent 1: Epidermal Structure and FunctionDate: Thursday 8 September 2016Time: 17.00-18.30Room: Munich

Chairs: Leopold Eckhart, Sirkku Peltonen

Concurrent talks are 8 minutes plus 2 minutes discussion.

17.00-17.10 Oral 014 [Poster 100] PNPLA1 Deficiency in Mice and Humans Leads to a Defect in the Synthesis of ω-O-Acylceramides S Grond,1 T Eichmann,1 S Dubrac,2 D Kolb,3 M Schmuth,2 J Fischer,4 G Haemmerle,1 R Zechner,1 A Lass1 and FP Radner1 1Institute

of Molecular Biosciences, University of Graz, Graz, Austria, 2Department of Dermatology and Allergology, Innsbruck Medical University, Innsbruck, Austria, 3Center for Medical Research, Medical University of Graz, Graz, Austria and 4Institute for Human Genetics, University Medical Center Freiburg, Freiburg i. Br., Germany

17.10-17.20 Oral 015 [Poster 113] PNPLA1 Defects in Patients with Ichthyosis and KO Mice Unveil PNPLA1 Irreplaceable Function in Epidermal omega–

acylceramide Synthesis and Skin Permeability Barrier M Pichery,1 A Huchenq,1 R Sandhoff,2 M Roy,1 M Severino-Freire,1 S Zaafouri,1 L Opalka,3 G Serre,1 J Mazereeuw-Hautier1 and N

Jonca1 1UDEAR-UMR 1056 Inserm, Toulouse, France, 2Lipid Pathobiochemistry Group, Department of Cellular and Molecular Pathology, German Cancer Research Center (DKFZ), Heidelberg, Germany and 3Department of Inorganic and Organic Chemistry, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic

17.20-17.30 Oral 016 [Poster 137] RIPK4 Maintains Epidermal Barrier Integrity by Regulating Tight Junction Protein Levels G Tanghe, C Urwyler, P De Groote, K Leurs, B Gilbert, R De Rycke, P Vandenabeele and W Declercq Inflammation Research Center -

Department of Biomedical Molecular Biology, VIB - Ghent University, Ghent, Belgium

17.30-17.40 Oral 017 [Poster 143] E-cadherin integrates EGFR Signaling and Mechanotransduction to Control Tissue Polarization and Barrier Formation M Rübsam,1 A Mertz,2 A Kubo,3 ER Dufresne,2 V Horsley,2 W Ziegler,5 SA Wickström,4 M Amagai3 and CM Niessen1 1Dermatology,

University of Cologne, Cologne, Germany, 2Yale University, New Haven, CT ,3Dermatology, Keio University School of Medicine, Tokyo, Japan, 4Max Planck Institute for Biology of Ageing, Cologne, Germany and 5Hannover Medical School, Hannover, Germany

17.40-17.50 Oral 018 [Poster 131] Epidermal Autophagy and Nucleophagy O Akinduro,1 CA Harwood,1 R O’Shaughnessy2 and D Bergamaschi1 1Centre for Cell Biology and Cutaneous Research, Blizard

Institute, Barts and The London SMD, QMUL, London, United Kingdom and 2Livingstone Skin Research Centre for Children, Institute of Child Health, UCL, London, United Kingdom

17.50-18.00 Oral 019 [Poster 107] Filaggrin Deficiency Impacts Cutaneous Microbiota P Zeeuwen,1 T Ederveen,2 D van der Krieken,1 H Niehues,1 J Boekhorst,2 S Kezic,3 M Zeeuwen-Franssen,4 M van Steensel,5 S van

Hijum2 and J Schalkwijk1 1Dermatology, Radboud University Medical Center, Nijmegen, Netherlands, 2Center for Molecular and Biomolecular Informatics, Radboud University Medical Center, Nijmegen, Netherlands, 3Coronel Institute of Occupational Health, Academic Medical Center, Amsterdam, Netherlands, 4Dermatology, Canisius Wilhelmina Hospital, Nijmegen, Netherlands and 5Division of Cancer Science, School of Medicine and Division of Biological Chemistry and Drug Development, School of Life Sciences, University of Dundee, Dundee, United Kingdom

18.00-18.10 Oral 020 [Poster 108] Targeting the Toll-like Receptor Pathway to Treat Scaling in the Autosomal Recessive Congenital Ichthyoses S Hassan, H Tagoe, G Youssef and R O’Shaughnessy UCL Institute of Child Health, London, United Kingdom

18.10-18.20 Oral 021 [Poster 142] CD271 Regulates Human Keratinocyte Functions through Phosphodiesterase 4 Binding A Marconi,1 F Truzzi,1 A Saltari,1 R Lotti,1 E Palazzo,1 M Quadri,1 P Schafer2 and C Pincelli1 1University of Modena and Reggio Emilia,

Modena, Italy and 2Celgene Corporation, Summit

18.20-18.25 Come and See my Poster (one slide, one minute)

Poster 090 Essential role of polarity protein Par3 for epidermal homeostasis through regulation of barrier function, keratinocyte

differentiation and stem cell maintenance NS Ali1, M Gomes1, R Bauer1, S Brodesser1, C Niemann2 and S Iden1 1CECAD, University of Cologne, Cologne, Germany and 2Center

for Biochemistry, Medical Faculty, University of Cologne, Germany, Cologne, Germany

Poster 111 Chronic exposure to environmental pollutants might predispose to epidermal barrier dysfunction evolving in atopic dermatitis A Elentner1, N Yannoutsos1, T Eichmann2, FP Radner2, M Schmuth1 and S Dubrac1 1Department of Dermatology, Venereology and

Allergology, Medical University of Innsbruck, Innsbruck, Austria and 2Institute of Molecular Biosciences, University of Graz, Graz, Austria

Poster 122 Polarity protein Par3 couples cell polarity and UV-B mediated stress response in the skin S Letzian, M Saynisch and S Iden CECAD, University of Cologne, Cologne, Germany

28

Concurrent 2: Melanoma, Melanocytes and PhotobiologyDate: Thursday 8 September 2016Time: 17.00-18.30Room: Salzburg

Chairs: Lise Boussemart, Lionel Larue


17.00-17.10 Oral 022 [Poster 182] Revertant Mosaicism in Congenital Melanocytic Naevi L Al-Olabi,1 W Baird,1 V Martins da Silva,1 A Virasami,2 A Thomas1 and VA Kinsler1 1Genetics and Genomic Medicine, UCL Institute of

Child Health, London, United Kingdom and 2Great Ormond Street Hospital for Children, London, United Kingdom

17.10-17.20 Oral 023 [Poster 450] Function of H2A Deubiquitinase 2A-DUB/Mysm1 in Skin Pigmentation and Melanoma Growth C Bruno, I Banik, C Kroeger, A Hainzl, C Wilms, M Wlaschek, K Scharffetter-Kochanek and MV Gatzka Dermatology, Ulm University,

Ulm, Germany

17.20-17.30 Oral 024 [Poster 534] Vitiligo: Studying the Dermal Compartment D Kovacs, E Bastonini, M Ottaviani, C Cota, E Migliano, M Dell’Anna and M Picardo San Gallicano Dermatologic Institute, Rome, Italy

17.30-17.40 Oral 025 [Poster 535] Keratinocytes Stem Cells are More Resistant to UVA Radiation than their Direct Progeny W Rachidi,1 E Metral,2 F Demarne,2 N Bechetoille2 and O Damour3 1INAC/SyMMES/LAN, CEA, Grenoble, France, 2Gattefosse, Saint

Priest, France and 3Banque de Tissus et Cellules, Hospices Civils de Lyon, Lyon, France

17.40-17.50 Oral 026 [Poster 522] Induction of the Progeroid/cancer Prone XP-like Phenotype by an Antimycotic Drug is Mediated via Reversible Downregulation of

DNA repair, an Update S Giovannini,1 L Weibel,2 C Braunsdorf,3 M Schaller,3 B Schittek,3 A Kulik,4 B Fehrenbacher,3 M Röcken,3 Y Kamenisch1 and M

Berneburg1 1Department of Dermatology, University Regensburg, Regensburg, Germany, 2University Children’s Hospital Zurich and Department of Dermatology, University Hospital Zurich, Zürich, Switzerland, 3Department of Dermatology, Eberhard Karls University, Tübingen, Germany and 4Department of Microbiology, Eberhard Karls University, Tübingen, Germany

17.50-18.00 Oral 027 [Poster 107] Human Skin Mast Cells Express Photoreceptors H Siiskonen,2 S Buscone,1 I Castellano Pellicena,1 A Smorodchenko,3 NE Uzunbajakava,4 NV Botchkareva,1 M Maurer3 and J Scheffel3

1Faculty of Life Sciences, Centre for Skin Sciences, Bradford, United Kingdom, 2Dermatology, Kuopio University Hospital, Kuopio, Finland, 3Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany and 4Philips Research Eindhoven, Eindhoven, Netherlands

18.00-18.10 Oral 028 [Poster 529] Ultraviolet-induced Loss of Subcutaneous Fat May Lead to the Deterioration of Skin Function E Kim, D Lee and J Chung Department of Dermatology, Seoul National University College of Medicine, Seoul, The Republic of Korea

18.10-18.20 Oral 029 [Poster 538] NADPH Oxidase-1 Plays a Key Role in UVB-induced Carcinogenesis H Raad, G Harfouche, M Hosseini and H Rezvani INSERM U1035, Bordeaux, France


Poster 512 ATM significantly protects against oxidative injury in human melanocyte associated with activation of Nrf2 pathway Z Jian and Q Zhang Xijing Hospital, Fourth Military Medical University, Xi’an, China

Poster 523 Ultraviolet-radiation (UV-R) affects the skin microbial load and influences the expression of antimicrobial peptides (AMPs) in

mice V Patra1, B Halwachs2, N Madhusudan2 and P Wolf1 1Research Unit for Photodermatology, Department of Dermatology, Medical

University of Graz, Graz, Austria and 2Institute of Pathology, Medical University of Graz, Graz, Austria

Poster 532 A “multi-omic” investigation of the effects of long wavelength ultraviolet light on primary human keratinocytes M Narzt1, IM Nagelreiter1, V Bochkov3, J Latreille4, M Fedorova5, Z Ni5, J Grillari2, E Tschachler1 and F Gruber1 1Dermatology, MUW,

Vienna, Austria, 2VIBT-BOKU, Vienna, Austria, 3University of Graz, Graz, Austria, 4ChanelPB, Paris, France and 5University of Leipzig, Leipzig, Germany

29

Concurrent 3: Adaptive Immunity and Immune RegulationDate: Thursday 8 September 2016Time: 17.00-18.30Room: Rotterdam

Chairs: Michael Hertl, Kerstin Steinbrink


17.00-17.10 Oral 030 [Poster 392] Imbalance of Mitochondrial Respiratory Chain Complexes in Epidermal Progenitor/Stem Cells Leads to Severe Skin

Inflammation D Weiland,1 H Hornig-Do,2 J Neuhaus,2 T Holzer,3 CM Niessen,4 D Tobin,5 B Brachvogel,3 R Wiesner2 and O Baris2 1Center for

Molecular Medicine Cologne, Cologne, Germany, 2Center for Physiology and Pathophysiology, Köln, Germany, 3Institute for Biochemistry, Köln, Germany, 4Department of Dermatology/CECAD, Cologne, Germany and 5Centre for Skin Sciences, Bradford, United Kingdom

17.10-17.20 Oral 031 [Poster 366] HSP70 Enhances the Production of Interferon-alpha by Plasmacytoid Dendritic Cells: Relevance for Cutaneous Lupus and Vitiligo

Pathogenesis C Jacquemin,1 S Guillet,1 J Rambert,2 D Thiolat,1 K Ezzedine,3 P Blanco,4 A Bertolotti,1 A Taieb,1 K Boniface1 and J Seneschal1

1INSERM U1035 Bordeaux University, Bordeaux, France, 2Aquiderm, Bordeaux, France, 3Université Paris Est Créteil CHU H.Mondor, Créteil, France and 4CHU Pellegrin Bordeaux, Bordeaux, France

17.20-17.30 Oral 032 [Poster 228] A Novel Splenic B1 Regulatory B Cell Subset with a Unique CD9+CD80+ Phenotype Suppresses an Allergic Disease via PI3K-Akt

Pathway Activation T Matsushita,1 M Fujimoto2 and K Takehara1 1Kanazawa University, Kanazawa, Japan and 2University of Tsukuba, Tsukuba, Japan

17.30-17.40 Oral 033 [Poster 282] The Contribution of Resident Memory T Cells to the Chronicity of Allergic Contact Dermatitis P Gamradt,1 L Laoubi,1 V Mutez,1 D Redoulès,2 A Schmitt,3 J Nicolas1 and M Vocanson1 1French Institute of Health and Medical

Research, Lyon, France, 2Pierre Fabre Dermo-Cosmetics, Toulouse, France and 3Research Institute Pierre Fabre, Toulouse, France

17.40-17.50 Oral 034 [Poster 279] Skin Dendritic Cells Show Increased Migration to Lymph Nodes in CD73 Deficient Mice Leading to Exacerbated Contact

Hypersensitivity Reactions A Pushkakevskaya, C Vilches, A Enk and K Mahnke Dpt. of Dermatology, University Hospital Heidelberg, Heidelberg, Germany

17.50-18.00 Oral 035 [Poster 242] Novel Immune Regulation by CD4+ T Cells via Cholesterol 25-hydroxylase Pathway H Takahashi,1 H Nomura,1 H Iriki,1 Y Mikami,2 Y Kanno,2 A Kubo,3 J O’Shea2 and M Amagai1 1Dermatology, Keio University, Tokyo,

Japan, 2NIAMS, National Institutes of Health, Bethesda, MD and 3Biochemistry, Keio University, Tokyo, Japan

18.00-18.10 Oral 036 [Poster 266] Tissue Antigen Expression Levels Control the Fundamental Decision between Tolerance and Autoimmunity DF Pinheiro,1 MM Maurano,1 MM Klicznik,1 R Holly,1 G Achatz-Straussberger,1 J Thalhamer,1 A Abbas,2 MD Rosenblum2 and IK

Gratz1 1Molecular Biology, University of Salzburg, Salzburg, Austria and 2University of California, San Francisco, San Francisco, CA

18.10-18.20 Oral 037 [Poster 444] Post-septic Immune-suppression Following Gram Positive Sepsis is Mediated by TLR Dependent Induction of Myeloid Derived

Suppressor Cells M Koeberle, T Biedermann and Y Skabytska Dermatology, Technical University Munich, Munich, Germany


Poster 245 Mechanisms of ER Stress Sensor Calreticulin (CRT) Exposure Controls the Destruction of Melanocytes by Enhanced CD8+ T Cell

Killing P Song, L Liu, G Wang, C Li and T Gao Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi’an, China

Poster 247 Disruption of the Epidermal Barrier Induces Regulatory T Cells in an IL-33 Dependent Fashion A Bruhs, T Schwarz and A Schwarz Department of Dermatology, University of Kiel, Kiel, Germany

Poster 300 Reprogramming Melanoma Resident Mast Cells to Establish Effective Tumor Defense S Kaesler1, F Wölbing1, Y Skabytska1, WE Kempf1, M Koeberle1, A Yazdi2, T Volz1, M Röcken2 and T Biedermann1 1Dermatology,

Technical University Munich, Munich, Germany and 2Dermatology, Eberhard Karls University, Tübingen, Germany

30

2016 Special Guest LectureThe Origin and End of the UniverseDate: Thursday 8 September 2016Time: 18.30-19.00Room: Munich

Introduced by: Tilo Biedermann

About the 2016 Special Guest LectureWhether you come out of the lecture depressed or optimistic, there should be plenty to talk about at the welcome reception following Prof Thomas Boller’s enthralling topic. The ESDR is honored to welcome Prof Boller to the annual Meeting.

Thomas BollerMax-Planck-Institut für Extraterrestrische PhysikMunichGermany

Professor Thomas Boller has worked at the Max-Planck Institut für extraterrestrische Physik in Garching since 1990. His main research interests include Active galactic Nuclei. During his work at MPE he has worked out the importance of Narrow-Line Seyfert 1 Galaxies for the

study of active galaxies resulting in an improved understanding of several problems raised by the Seyfert phenomenon. He is lecturing all courses on Astrophysics at the Johann Wolfgang Goethe-Universität in Frankfurt am Main since 1996 for students of Physics and Astronomy. Since 2004 he is also a Professor for Astrophysics at the University of Padova. Professor Boller is a member of the international Sloan-Collaboration, the XMM Survey Science Consortium and the XEUS Astrophysical working groups. He has organized several international workshop on all aspects of AGN research activities.

Professor Boller has been awarded with the Michael and Biserka Baum Preis for his outstanding research on ActiveGalactic Nuclei at MPE and his excellent teaching at the Goethe University Frankfurt and became a full member of the Academia Europaea, Section Physics and Engineering in 2011.

31

FRIDAY

32

Intravenous Immunoglobulins in Dermatological Autoimmune Diseases Date: Friday 9 September 2016Time: 08.30-09.30Room: Rotterdam

Chair: Alexander Enk (Heidelberg)

PROGRAM

08.30-08.50 Update of the European guidelines on the use of IVIg: indications, therapy management and mode of action Alexander Enk (Heidelberg, Germany)

08.50-09.10 Clinical Use of IVIg in patients with pemphigus and mucous membrane pemphigoid Enno Schmidt (Lübeck, Germany)

09.10-09.30 Use of IVIg in preclinical models of autoimmune bullous diseases Rüdiger Eming (Marburg, Germany)

This educational symposium is supported by Biotest.

NOTES..............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................

33

Recent Advances in Acne & Rosacea Research – “Neurogenic inflammation”Date: Friday 9 September 2016Time: 08.30-09.30Room: Salzburg

Chair: Martin Steinhoff (Dublin)

PROGRAM

08.30-08.45 New Insights Into Acne and Rosacea - Implications of Neuroinflammation, Pain and Itch Martin Steinhoff (Dublin, Ireland)

08.45-09.15 G Protein-coupled Receptors: Dynamic Machines for Signaling Neurogenic Inflammation, Pain and Itch Nigel Bunnett (Calgary, Canada)

09.15-09.30 Neuro-inflammation as a Therapeutic Target Martin Steinhoff (Dublin, Ireland)

This educational symposium is supported by Galderma.

NOTES..............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................

34

Skin Aging: How to Overcome Tissue DeclineDate: Friday 9 September 2016Time: 08.30-09.30Room: Copenhagen

Chair: TIlo Biedermann (Munich, Germany)

PROGRAM

08.30-08.45 Ultraviolet Radiation, Pollution and Repair of Tissue Damage/Skin Aging Mark Berneburg (Regensburg, Germany)

08.45-09.00 Photoaging: Daily UV Exposures and Contribution of Longwave UVA1 Francoise Bernerd (Aulnay, France)

09.00-09.15 Aging in Different Ethnic Groups Marion Nielsen (Clichy, France)

09.15-09.30 Stem Cells in Aging Karin Scharffetter-Kochanek (Ulm, Germany)

This educational symposium is supported by L’Oréal.

NOTES..............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................

35

2016 Celgene ESDR Guest LectureDysregulated Immune Responses and AutoimmunityDate: Friday 9 September 2016Time: 9.30-10.00Room: Munich

Introduced by: Michel Gilliet

Brigitta Stockinger PhDResearch DirectorThe Francis Crick InstituteLondonUK

Brigitta Stockinger obtained her PhD in Biology at the University of Mainz and then did postdoctoral studies in London and Cambridge, followed by a postdoc at the Cancer Research Institute in Heidelberg. In 1985 she became a member of the Basel Institute for Immunology where she stayed until 1991. Her time at the Basel Institute shaped her career significantly as in this institute young researchers were given complete freedom to choose their research direction thus gaining independence earlier than would otherwise have been possible.

In 1991 she became a group leader in the Division of Molecular Immunology of the National Institute for Medical Research in Mill Hill. Her research initially focused on immune tolerance using T cell receptor transgenic mouse models. Following on her interest turned to immunological memory focusing on CD4 memory T cells, their generation and survival.

Her lab became involved in infection research following her discovery of the differentiation factors for Th17 generation. Inflammation and infection have been a focus of her research since. More recently her lab discovered the importance of the transcription factor aryl hydrocarbon receptor (AhR), an environmental sensor, in the immune system.

She obtained an ERC Advanced Investigator grant in 2009 to study physiological functions of AhR and in 2013 she was awarded a Wellcome Senior Investigator Grant that will continue and expand the investigation of AhR in innate and adaptive immune cells. She became a Fellow of the Academy of Medical Sciences in 2005, an EMBO fellow in 2008 and a Fellow of the Royal Society in 2013.

Selected Publications

Martin, B; Hirota, K; Cua, DJ; Stockinger, B and Veldhoen, M (2009) Interleukin-17-producing γδ T cells selectively expand in response to pathogen products and environmental signals. Immunity 31, 321-330

Veldhoen, M., Hocking, R.J., Flavell, R.A. and Stockinger, B. (2006) Signals mediated by transforming growth factor-č initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease. Nat.Immunol 7, 1151-1156

Veldhoen, M., Hocking, R.J., Atkins, C.J., Locksley, R.M., and Stockinger, B. (2006) TGF-beta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17 producing T cells. Immunity 24, 179-189

NOTES..............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................

36

Concurrent 4: Genetics and Cell Based TherapyDate: Friday 9 September 2016Time: 10.00-11.30Room: Munich

Chairs: John McGrath, Julia Reichelt


10.00-10.10 Oral 038 [Poster 148] Identification of Multiple Genetic Loci Associated with Severe Acne Vulgaris M Simpson,1 AA Navarini,2 CH Smith3 and J Barker3 1Genetics and Molecular Medicine on behalf of Acne Genetics Consortium, Kings

College London, London, United Kingdom, 2Genetics and Molecular Medicine, Kings College London, London, United Kingdom and 3St John’s Institute of Dermatology, Kings College London, London, United Kingdom

10.10-10.20 Oral 039 [Poster 020] Clinico-pathological and Molecular Characterization of Autosomal Recessive Epidermolysis Bullosa Simplex Due to EXPH5

(exophilin-5) Mutations E Rashidghamat,1 J Mellerio,1 A Martinez2 and J McGrath1 1St John’s Institute of Dermatology, London, United Kingdom and 2Great

Ormond Street Hospital for Sick Children, London, United Kingdom

10.20-10.30 Oral 040 [Poster 151] Postzygotic KITLG Mutation in a Congenital Non-progressive Linear Nevoid Hyperpigmentation A Sorlin,1 A Maruani,2 J Rivière,1 Y Duffourd,1 P Kuentz,1 T Jouan,1 C Thauvin-Robinet,1 J Thevenon,1 L Faivre1 and P Vabres3

1Laboratoire GAD - Génétique des Anomalies du Développement, Dijon, France, 2Service de Dermatologie, CHU de Tours, Université François Rabelais, Tours, France and 3Dermatologie, CHU de Dijon, Dijon, France

10.30-10.40 Oral 041 [Poster 274] AP1S3 Mutations Cause Cutaneous Autoinflammation by Disrupting Autophagy and Up-regulating IL-36 Production in

Keratinocytes SK Mahil,1 N Setta-Kaffetzi,1 R Trembath,1 CH Smith,1 P Di Meglio,2 J Barker1 and F Capon1 1Division of Genetics and Molecular

Medicine, King’s College London, United Kingdom and 2Mill Hill Laboratory, The Francis Crick Institute, London, United Kingdom

10.40-10.50 Oral 042 [Poster 132] Identification of Novel Pathways Linked to the Pathogenesis of Recessive X-Linked Ichthyosis F McGeoghan,1 M Menon,1 P Dewan,1 M Caley,1 M Donaldson2 and EA O’Toole1 1Centre for Cell Biology and Cutaneous Research,

Barts & the London School of Medicine and Dentistry, London, United Kingdom and 2Dermatology TA, GSK, London, United Kingdom

10.50-11.00 Oral 043 [Poster 172] DNA Methylation Targeting to Rescue Chronological and Pathological Loss of Skin Elasticity S Pain,1 V Bardey,1 V André-Frei,1 L Moulin2 and R Debret2 1BASF Beauty Care Solutions, Lyon, France and 2LBTI-UMR5305 -IBCP,

Lyon, France

11.00-11.10 Oral 044 [Poster 157] Efficacy and Mechanism of Amlexanox for Potential Treatment of Recessive Dystrophic Epidermolysis Bullosa VS Atanasova,1 C Gruber,2 M Chen,3 J Uitto1 and A South1 1Dermatology and Cutaneous Biology, Thomas Jefferson University,

Philadelphia, PA, 2Dermatology, EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Paracelsus Medical University, Salzburg, Austria and 3Dermatology, University of Southern California, Los Angeles, CA

11.10-11.20 Oral 045 [Poster 169] Regeneration of a Functional Epidermis at a Large, Long-standing Wound by Gene-corrected Autologous Epidermal Stem Cells JW Bauer,2 EM Murauer,1 J Koller,2 L De Rosa,3 E Enzo,3 S Carulli,4 W Muss,5 E Mayr,1 G Pellegrini3 and M De Luca3 1EB House

Austria, Research Program for Molecular Therapy of Genodermatoses, Dept of Dermatology, Paracelsus Medical University, Salzburg, Austria, 2Dept of Dermatology, Paracelsus Medical University, Salzburg, Austria, 3Center for Regenerative Medicine “Stefano Ferrari”, University of Modena and Reggio Emila, Modena, Italy, 4Holostem Terapie Avanzate S.r.l., Modena, Italy and 5Institute of Pathology, Paracelsus Medical University, Salzburg, Austria


Poster 156 First Report of Digenic Inheritance in Pustular Psoriasis S Twelves1, D Burden2, S Marta3, Z Bata-Csörgö3, S Choon4, M Mockenhaupt5, CH Smith1, F Capon1 and J Barker1 1Division of Genetics

and Molecular Medicine, King’s College London, London, United Kingdom, 2Department of Dermatology, University of Glasgow, Glasgow, United Kingdom, 3Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary, 4Department of Dermatology, Hospital Sultanah Aminah, Johor Bahru, Malaysia and 5Department of Dermatology, Medical Center-University of Freiburg, Freiburg, Germany

Poster 160 Demonstration of the Critical Role of the Liver in Systemic PPi Homeostasis using a Novel Abcc6 Knockout Rat Model of PXE Q Li1, K van de Wetering2, J Sundberg3 and J Uitto1 1Thomas Jefferson University, Philadelphia, PA, 2Netherlands Cancer Institute,

Amsterdam, Netherlands and 3The Jackson Laboratory, Bar Harbor, ME

Poster 164 CRISPR/Cas9-mediated Gene Repair in the COL7A1 Gene S Hainzl1, T Kocher1, EM Murauer1, F Larcher3, M Steiner4, JW Bauer2, J Reichelt1 and U Koller1 1EB House Austria, Research

Program for Molecular Therapy of Genodermatoses, Department of Dermatology, University Hospital of the Paracelsus Medical University, Salzburg, Austria, 2Department of Dermatology, Paracelsus Medical University, Salzburg, Austria, 3Epithelial Biomedicine Division, CIEMAT, Madrid, Spain and 4Third Medical Department, Paracelsus Medical University Salzburg, Austria, Laboratory for Immunological and Molecular Cancer Research, Salzburg, Austria

37

Concurrent 5: Wound Healing and Tissue RemodellingDate: Friday 9 September 2016Time: 10.00-11.30Room: Salzburg

Chairs: Sabine Eming, Marta Szell


10.00-10.10 Oral 046 [Poster 552] Combined Loss of Integrins α1β1 and α2β1 Results in Reduced Angiogenesis in Mice S Ghatak,1 S Niland,2 J Schulz,1 F Wang,1 C Mauch,1 T Krieg,1 P Zigrino1 and B Eckes1 1Dermatology, University of Cologne, Cologne,

Germany and 2Institute of Physiological Chemistry & Pathobiochemistry, Münster, Germany

10.10-10.20 Oral 047 [Poster 568] p63 Regulation of the iRHOM2/ADAM17 Pathway in Keratinocytes P Arcidiacono, A Chikh and DP Kelsell Centre for Cell Biology & Cutaneous Research, Blizard Institute Queen Mary University,

London, United Kingdom

10.20-10.30 Oral 048 [Poster 219] STAT5 Activation in the Dermal Papilla Is Important for Hair Follicle Growth Phase Induction, Hair Follicle Regeneration and

Wound Healing J Legrand, R Villani, E Roy and K Khosrotehrani Centre for Clinical Research, The University of Queensland, Brisbane, QLD,

Australia

10.30-10.40 Oral 049 [Poster 569] Loss of Collagen 7 Drives HIF-1 alpha Induced Pro-angiogenic Pathways MA Krupiczojc,1 MP Caley,1 ST Marsh,1 M Donaldson,2 VL Martins1 and EA O’Toole1 1Centre for Cutaneous Research, Blizard Institute,

London, United Kingdom and 2Dermatology TA, GSK, Uxbridge, United Kingdom

10.40-10.50 Oral 050 [Poster 573] Fibroblast Derived MMP-14 is the Main Collagenase for Skin Homeostasis P Zigrino,1 J Brinckmann,2 A Niehoff,3 Y Lu,4 N Giebeler,1 B Eckes,1 K Kadler4 and C Mauch1 1Department of Dermatology, University

of Cologne, Cologne, Germany, 2Department of Dermatology, University of Lübeck, Lübeck, Germany, 3Institute of Biomechanics and Orthopaedics, University of Cologne, Cologne, Germany and 4Faculty of Life Sciences, Wellcome Trust Centre for Cell-Matrix Research, Manchester, United Kingdom

10.50-11.00 Oral 051 [Poster 080] A Novel Gene Ahed Plays Key Roles in Proliferation, Survival, and Differentiation of Murine Epidermis M Takaishi,1 M Tokunaga,2 C Kokubu,2 J Takeda2 and S Sano1 1Dermatology, Kochi Medical School, Kochi University, Nankoku, Japan

and 2Genome Biology, Graduate School of Medicine, Osaka University, Suita, Japan

11.00-11.10 Oral 052 [Poster 557] Targeted Genetic Alteration in Hyaluronan Catabolism Delays Wound Healing in Mice J Muto,1 D Watanabe1 and RL Gallo2 1Department of Dermatology, Aichi Medical University, Nagakute, Japan and 2Department of

Dermatology, University of California, San Diego, La Jolla, CA

11.10-11.20 Oral 053 [Poster 562] MicroRNA-132, A Promising Target for Wound Therapy X Li 1, D Li1, A Wang2, W Lohcharoenkal1, J Grünler3, S Narayanan3, E Sonkoly1, A Pivarcsi1, C Sergiu-Bogdan3, M Ståhle1, N Xu

Landén1 1Molecular Dermatology Research Group, Unit of Dermatology and Venereology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden 2Department of Dermatology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China 3Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden


Poster 547 Skin Wound Inflammation Modulated by IL-17 Producing Macrophages is Dependent on IL-23 JS Lee1, M Rodero2, D Moi1, J Patel2, R Mazzieri1 and K Khosrotehrani1 1Diamantina Institute, UQ, Brisbane, QLD, Australia and

2Centre for Clinical Research, UQ, Brisbane, QLD, Australia

Poster 551 Nrf2 Activation Enhances Cutaneous Wound Healing by Expansion of Hair Follicle Stem Cell Populations SS Muzumdar1, H Hiebert1, E Haertel1, W Bloch2, S Werner1 and M Schäfer1 1Institute of Molecular Health Sciences, ETH Zurich,

Zurich, Switzerland and 2Institute of Cardiovascular Research and Sport Medicine, German Sport University Cologne, Cologne, Germany

Poster 555 Systemic HMGB1 Administration Ameliorates Bleomycin-induced Skin Fibrosis by Promoting Accumulation of Bone Marrow-

derived Mesenchymal Stem Cells to the Lesion Y Komurasaki1, E Aikawa1, I Katamaya2 and K Tamai1 1Stem cell therapy science, Osaka University, Suita-shi, Japan and

2Dermatology, Osaka University, Suita-shi, Japan

38

Concurrent 6: Antimicrobial Immunity and Allergic InflammationDate: Friday 9 September 2016Time: 10.00-11.30Room: Rotterdam

Chairs: Alexander Navarini, Thomas Werfel


10.00-10.10 Oral 054 [Poster 355] A Human in vivo Model of a Cutaneous Memory B Cell Immune Response to Skin Antigen Challenge IU Egbuniwe,1 W Alwan,1 SN Karagiannis,1 A Akbar,2 FO Nestle1 and KE Lacy1 1St John’s Institute of Dermatology, London, United

Kingdom and 2Division of Infection and Immunity, University College London, London, United Kingdom

10.10-10.20 Oral 055 [Poster 267] Influence of Mouse beta-defensin 14 on Skin Barrier Repair and Bacterial Growth E Proksch, C Neumann, J Harder and N Graumann Dermatology, University of Kiel, Kiel, Germany

10.20-10.30 Oral 056 [Poster 343] Imatinib Triggers Antimycobacterial Activity in Glucocorticoid-Treated Human Macrophages J Steiger and M Fabri Department of Dermatology, University of Cologne, Cologne, Germany

10.30-10.40 Oral 057 [Poster 322] Mast Cells Control the Number of c-Kit+CD11b+ Multipotent Progenitor-like cells for Regulating Tissue-resident Macrophages S Wakabayashi, Y Nakamura and H Matsue Dermatology, Chiba University, Chiba, Japan

10.40-10.50 Oral 058 [Poster 393] KLK6-mediated Down-regulation of Keratin10 Is Commonly Employed by Skin-tropic Viruses to Propagate in Skin and Is

Required for Blister Formation in VZV Infection C Tommasi,1 D Depledge,2 D Duddy,1 M Jones,2 H Pfister,3 B Akgul,3 J Breuer2 and R O’Shaughnessy1 1Immunobiology, UCL Institute

of Child Health, London, United Kingdom, 2Infection and Immunity, UCL, London, United Kingdom and 3Institut fur Virologie, Uniklinik, Cologne, Germany

10.50-11.00 Oral 059 [Poster 315] Air Pollution Activates Aryl Hydrocarbon Receptor of Undifferentiated Keratinocytes, Leading to Atopic Dermatitis-like

Pathologies T Hidaka,1 EH Kobayashi,2 T Suzuki2 and M Yamamoto2 1Dermatology, Tohoku Univ., Sendai, Japan and 2Medical Chemistry, Tohoku

Univ., Sendai, Japan

11.00-11.10 Oral 060 [Poster 376] Grass Pollen-specific Immunotherapy entails Systemic Increase of Regulatory B cells and Shift in Th17 Cell Compartments CA Jakwerth,1 UM Zissler,1 FM Gürth,1 Z Hajdu,2 C Schmidt-Weber1 and AM Chaker2 1ZAUM - Center of Allergy and Environment,

Technische Universität München (TUM) and Helmholtz Center Munich, Member of the German Center for Lung Research (DZL), Munich, Germany and 2ENT-Department, Klinikum rechts der Isar der Technischen Universität München (TUM), Munich, Germany

11.10-11.20 Oral 061 [Poster 356] IL-9 expression is an Activation-dependent and Transient Condition of TH2 Cells C Micossé,1 AP Frei,2 L Borradori,1 D Yerly3 and C Schlapbach1 1Department of Dermatology, Inselspital, Bern University Hospital,

Bern, Switzerland, 2Baxter Laboratory in Stem Cell Biology, Department of Microbiology and Immunology, Stanford University, Stanford, CA and 3Division of Allergology, Inselspital, Bern University Hospital, Bern, Switzerland


Poster 380 Age Dictates a Steroid Resistant Cascade of wnt5a, Transglutaminase-2 and Leukotrienes in Inflamed Airways K Dietz1, M de los Reyes Jiménez1, E Gollwitzer2, C Schmidt-Weber1, AM Chaker3, B Marsland2 and J Esser-von Bieren1 1Center

of Allergy and Environment (ZAUM), Technical University of Munich and HelmholtzCentre Munich, Munich, Germany, 2Faculty of Biology and Medicine, Université de Lausanne, Epalinges, Switzerland and 3Department of Otolaryngology, Allergy Section, Klinikum rechts der Isar, TUM, Munich, Germany

Poster 398 Novel Lymphocyte Stimulation Tests Using ex vivo Expanded Skin-infiltrating T Cells From Severe Drug Eruptions T Fujiyama1, H Hashizume2, T Umayahara1, T Ito1 and Y Tokura1 1Dermatology, Hamamatsu University School of Medicine,

Hamamatsu, Japan and 2Dermatology, Shimada City Municipal Hospital, Shimada, Japan

Poster 419 RNase 7 Promotes Uptake and Sensing of Self-DNA by Human Keratinocytes and Reduces HSV-1 Infection of Human

Keratinocytes V Kopfnagel1, K Baumert1, SWagenknecht1, J Harder2, M Kleine3 and T Werfel1 1Division of Immunodermatology and Allergy

Research, Hannover Medical School, Hannover, Germany, 2Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany and 3PLANTON GmbH, Kiel, Germany

39

Translational Medicine: “Signal Transduction and Disease Pathogenesis”Date: Friday 9 September 2016Time: 13.00-14.30Room: Rotterdam

Chair: Sean Whittaker (UK)

Key Learning Objectives

* Understand the role of molecular signaling pathways leading to dermatological diseases* Understand the current clinical research efforts targeting intracellular pathways for therapeutic intervention

PROGRAM

13.00-13.05 Welcome and Introduction Sean Whittaker (UK)

13.05-13.25 Common and Separate Signaling Pathways in Psoriasis and Eczema Hervé Bachelez (France)

13.25-13.45 Molecular Pathways Conferring the Risk of Lupus Myles Lewis (UK)

13.45-14.05 Intracellular Signaling Pathways in Cutaneous Lymphoma Sean Whittaker (UK)

14.05-14.25 Targeted Therapeutics for Inflammation and Immunology Peter Schafer (USA)

14.25-14.30 Q & A

This educational symposium is supported by Celgene.

NOTES....................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................

40

Skin Aging & Pigmentation Date: Friday 9 September 2016Time: 13.30-14.30Room: Salzburg

Chairs: Véronique Raoul & Hiroshi Shimizu

PROGRAM

13.30-13.35 Introduction Hiroshi Shimizu (Sapporo, Japan) 13.35-13.45 Genome Wide Association studies & Aging: Stakes and Perspectives Jean-François Zagury (Paris, France)

13.45-13.55 Genome Wide Association Studies & Pigmented Irregularities Frédérique Morizot (Paris, France)

13.55-14.05 New Insights in Stem Cell Research & Age-related Changes in Skin and Hair Pigmentation Emi K. Nishimura (Tokyo, Japan)

14.05-14.15 Cell Senescence & Skin Aging Johannes Grillari (Vienna, Austria)

14.15-14.30 Awards Véronique Raoul (Paris, France)

This educational symposium is supported by Chanel.

NOTES....................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................

41

2016 ESDR Guest LectureMapping the Genetic Architecture of Common Complex DiseaseDate: Friday 9 September 2016Time: 14.30-15.00Room: Munich

Introduced by: Jonathan Barker

Gonçalo AbecasisCenter for Statistical GeneticsUniversity of MichiganUSA

Goncalo Abecasis is a Professor of Biostatistics. He received his D.Phil. in Human Genetics from the University of Oxford in 2001 and joined the faculty at the University of Michigan in the same year. Dr. Abecasis’ research focuses on the development of statistical tools for the identification and study of genetic variants important in human disease. Software developed by Dr. Abecasis at the University of Michigan is used in several hundred gene-mapping projects around the world.

The central aspect of his research is the identification and characterization of genes determining human variation and disease. In particular, he has focused on developing analytical methods and statistical tools that will facilitate the mapping of complex traits and allow geneticists to realize the benefits of new high-throughput technologies in the lab. Much of his research has focused on the use of linkage disequilibrium in the mapping of complex disease susceptibility genes. Linkage disequilibrium based mapping strategies search for short segments of ancestral chromosomes shared among present day individuals. High-throughput technologies allow fine-scale characterization of genetic variation and have made these searches possible.

Quantitative Trait Mapping: He has proposed a test of association in general pedigrees that uses all available information on each individual’s ancestry to separate population substructure from linkage disequilibrium (Abecasis et al. 2000a; Abecasis et al. 2000b). Using this model, he has investigated the role of various angiotensin-converting enzyme (ACE) gene polymorphisms on circulating ACE levels in blood. The ACE gene, and an Alu insertion-deletion polymorphism it contains, has generated intense interest because of its possible role in hypertension and heart disease. He evaluated the effect of variants in the gene in Jamaican and British samples. The data show that the I/D polymorphism is not the major functional variant in this gene and suggest a number of nearby variants as candidates (McKenzie et al. 2001).

Characterizing Genetic Variation in Humans: The success of mapping strategies based on allelic association and linkage disequilibrium is going to depend, to a large part, on the extent of linkage disequilibrium in the populations being studied. The observation that linkage disequilibrium extends for long distances and that most chromosomes are mosaics of relatively common short haplotypes is a critical underpinning of the NIH haplotype map initiative. He has developed graphical tools that allow scientists to explore and summarize patterns of disequilibrium in regions of interest (Abecasis and Cookson 2000). In addition he has

provided some of the first detailed, large-scale descriptions of linkage disequilibrium in the genome (Moffatt et al. 2000; Abecasis et al. 2001d). His observations demonstrated that linkage disequilibrium extends further than theoretical predictions in much of the genome and suggested that it is organized in cluster-like structures.

Computational Tools: A significant challenge in the fine-scale characterization of genomic variation is the sheer amount of data that must be considered. Most current analytical methods focus on the analysis of relatively small numbers of markers (10 to 50) and cannot handle the large numbers of linked variants (1000) that can be assayed using high-throughput technologies. He has described and implemented novel, very efficient algorithms that exploit the structure of genetic data in pedigrees (Abecasis et al. 2002) and populations (Abecasis et al. 2001c) to provide extremely fast solutions to traditional problems. Specifically, he showed that allowing for the small number of recombination events between consecutive markers could greatly simplify likelihood calculations in dense genetic maps. He also described a representation of gene flow within pedigrees that uses sparse binary trees to summarize redundancies in genetic data and further simplifies likelihood calculations (Abecasis et al. 2002). Separately, he showed how population and family data could be combined in haplotype estimation and proposed a divide-and-conquer algorithm for tackling longer haplotypes (Abecasis et al. 2001c). Together, these methods can also handle very large datasets and enable construction of the first chromosome wide linkage disequilibrium map (Dawson et al. 2002).

Practical Challenges: A final aspect of his research concerns the challenges of handling real, sometimes imperfect data. He has investigated the effects of genotyping error on quantitative trait analyses (Abecasis et al. 2001a). In addition, he has proposed strategies for genotype error detection (Abecasis et al. 2002) and identifying misspecified relationships (Abecasis et al. 2001b). The motivation for his research comes from the day-to-day challenges encountered in the gene-mapping projects where he is involved. This research has been motivated by collaboration with researchers seeking to identify genes predisposing to diabetes (Dr. Michael Boehnke, University of Michigan), glaucoma and age-related macular degeneration (Drs. Julia Richard and Anand Swaroop, University of Michigan), schizophrenia (Dr. Maria Karayiorgou, Rockefeller University) and aging related traits (David Schlessinger, National Institutes of Aging).

The Future: He believes that further successes in the area of complex disease gene identification will require even better computational tools and further improved statistical methods that are able to tackle the large single nucleotide polymorphism datasets (SNP) now being collected. Some of the challenges for these tools include haplotype estimation, evaluation of linkage evidence through simulation, and improved detection and modeling of possible genotype and pedigree errors.

42

Concurrent 7: Skin Cancer and Epidermal RegulationDate: Friday 9 September 2016Time: 15.00-16.30Room: Salzburg

Chairs: Matthias Schmuth, Edel O’Toole


15.00-15.10 Oral 062 [Poster 115] Centrosomes are Required for the Development of the Skin Epidermis and Hair Folllicles M Damen, E Soroka and H Bazzi Dermatology, University Hospital of Cologne, Cologne, Germany

15.10-15.20 Oral 063 [Poster 081] Genomic Engineering using CRISPR-Cas9 in the Human Sweat Gland Cell Line NCL-SG3 Shows Contribution of TMEM16A to

Ca2+-activated Cl- Secretion S Fischer,1 J Trothe,1 Ü Pul,1 D Hartmann2 and T Ertongur-Fauth1 1BRAIN AG, Zwingenberg, Germany and 2Department of

Dermatology and Allergology, Ludwig-Maximilians-University, Munich, Germany

15.20-15.30 Oral 064 [Poster 528] Autophagy Deficient Keratinocytes Display Increased DNA Damage and Senescence Markers After Oxidative Stress in vitro and in

vivo X Song,1 M Narzt,1 IM Nagelreiter,1 P Hohensinner,2 E Tschachler,1 J Grillari3 and F Gruber1 1Dermatology, Medical University of

Vienna, Vienna, Austria, 2Internal Medicine II, Medical University of Vienna, Vienna, Austria and 3VIBT - CD Lab Skin Aging, BOKU, Vienna, Austria

15.30-15.40 Oral 065 [Poster 490] The Effect of Dsg2 in the SSC Cells on Exosome Contents, Release, and Effects on Recipient Fibroblasts A Overmiller,1 J Pierluissi,1 P Wermuth,1 U Martinez-Outschoorn,1 A Luginbuhl,1 J Curry,1 L Harshyne,1 J Wahl,2 A South1 and MG

Mahoney1 1Thomas Jefferson University, Philadelphia, PA and 2University of Nebraska, Lincoln, NE

15.40-15.50 Oral 066 [Poster 472] Loss of Laminin α3 Drives SCC Invasion via ROCK Signalling M Caley,1 V Martins,1 K Moore,2 M Lashari,1 V Kähäri,3 L Nissinen,3 M Donaldson,4 J Marshall2 and EA O’Toole1 1Centre for Cell

Biology and Cutaneous Research, Barts and the London SMD, QMUL, London, United Kingdom, 2Barts Cancer Institute, Barts and The London School of Medicine and Dentistry, London, United Kingdom, 3Dermatology, University of Turku, Turku, Finland and 4Dermatology TA, GSK, Uxbridge, United Kingdom

15.50-16.00 Oral 067 [Poster 508] Phospholipase D-activated mTOR Signaling Underlies the Epidermal Malignancy Phenotype in a Zebrafish Matriptase Over-

activation Mutant J Armistead, J Hatzold and M Hammerschmidt Developmental Biology, University of Cologne, Cologne, Germany

15.00-16.10 Oral 068 [Poster 297] IgE Strongly Promotes Inflammation-driven Skin Carcinogenesis MD Hayes, G Crawford, R Castro-Seoane and J Strid Medicine, Imperial College London, London, United Kingdom

15.10-16.20 Oral 069 [Poster 491] Cellular Response Patterns to Single MEK Inhibition Correlate with the Efficacy of Combined MEK/CDK4,6 Targeting in Melanoma C Posch,3 M Sanlorenzo,1 J Ma,2 ST Kim,2 M Zekhtser2 K Rappersberger3 and S Ortiz-Urda2 1Department of Medical Sciences,

University of Turin, Turin, Italy, 2Dermatology, University of California San Francisco, San Francisco, CA and 3Dermatology, The Rudolfstiftung Hospital, Vienna, Austria


Poster 447 A Synergism Between Arsenic-induced Epigenetic Modification and Inflammatory Promotion in a Novel Skin Equivalent During

Arsenic Carcinogenesis W Liao1, J Lu2, C Lee3, C Lan4, J Chang5, C Chai6 and H Yu7 1Department of Biotechnology, College of Life Science, Kaohsiung

Medical University, Kaohsiung, Taiwan, 2Graduate Institute of Medical Science, Kaohsiung Medical Unversity, Kaohsiung, Taiwan, 3Department of Dermatology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan, 4Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 5College of Medicine, China Medical University, Taichung, Taiwan, 6Department of Pathology, Kaohsiung Medical University and Hospital, Kaohsiung, Taiwan and 7National Institute of Environmental Sciences, National Health Research Institutes, Miaoli County, Taiwan

Poster 462 Reticular Dermis Is More Conductive to Invasion of Squamous Cell Carcinoma Than Papillary Dermis in Human Fibroblast

Derived Skin Models Emulating Skin Aging M Hogervorst1, M Rietveld2, A El Ghalbzouri2 and Fd Gruijl2 1Biomimiq, Aeon Astron Europe B.V., Leiden, Netherlands and

2Dermatology, Leiden University Medical Center, Leiden, Netherlands

Poster 465 Ultraviolet (UV)-A Irradiation Induces Melanoma Invasion via Enhanced Warburg Effect T Baban1, Y Kamenisch2, W Schuller1, A von Thaler1, T Sinnberg1, J Bauer1, G Metzler1, C Garbe1, M Röcken1 and M Berneburg2

1Department of Dermatology, Eberhard Karls University, Tübingen, Germany and 2Department of Dermatology, University Regensburg, Regensburg, Germany

43

Concurrent 8: Clinical OutcomesDate: Friday 9 September 2016Time: 15.00-16.30Room: Munich

Chairs: Amy Foulkes, Chris Griffiths


15.00-15.10 Oral 070 [Poster 027] Association of Atopic Dermatitis with Cardiometabolic Diseases and Risk Factor M Standl,1 E Rodríguez,2 H Baurecht,2 A Peters,1 J Schmitt3 and S Weidinger2 1Institute of Epidemiology, Helmholtz Zentrum

München–German Research Center for Environmental Health, Neuherberg, Germany, 2Dept of Dermatology, Allergology and Venereology, University Hospital Schleswig-Holstein, Campus Kiel, Germany and 3Center for Evidence-Based Healthcare, University Hospital Carl Gustav Carus, Technical University Dresden, Germany

15.10-15.20 Oral 071 [Poster 033] A Novel, Nonsteroidal, Topical, Anti-Inflammatory, Phosphodiesterase Inhibitor, Crisaborole Topical Ointment, 2%, in Two Phase

3 Studies in Children and Adults with Mild to Moderate Atopic Dermatitis AS Paller,1 WL Tom,2 RS Call,3 L Eichenfield,2 D Forsha,4 W Rees,5 M Spellman,6 LT Zane6 and AA Hebert7 1Northwestern University,

Feinberg School of Medicine, Chicago, IL, 2Rady Children’s Hospital, San Diego, CA, 3Clinical Research Partners, Richmond, VA, 4Jordan Valley Dermatology & Research Center, West Jordan, UT, 5PI-Coor Clinical Research, Burke, VA, 6Anacor Pharmaceuticals, Inc., Palo Alto, CA and 7University of Texas Health Science Center at Houston, Houston, TX

15.20-15.30 Oral 072 [Poster 037] Evolutionary Risk Management of agr Locus is Important for S. aureus Adaptation in the Skin of Atopic Dermatitis Y Nakamura,1 Y Inoue,2 A Takaya,3 H Takahashi,4 Y Kusuya,4 Y Katayama,1 N Shimojo2 and H Matsue1 1Dermatology, Chiba University,

Chiba, Japan, 2Pediatrics, Chiba University, Chiba, Japan, 3Microbiology and Molecular Genetics, Chiba University, Chiba, Japan and 4Division of Bio-resources, Medical Mycology Research Center, Chiba University, Chiba, Japan

15.30-15.40 Oral 073 [Poster 005] Humanized Anti-interleukin-31 Receptor A Antibody Nemolizumab (CIM331) Suppresses Pruritus and Improves Eczema in

Patients with Moderate-to-severe Atopic Dermatitis K Kabashima,8 M Furue,1 J Hanifin,2 G Pulka,3 I Mlynarczyk,4 A Wollenberg,5 R Galus,6 R Mihara,7 T Ethoh9 and T Ruzicka5 1Kyushu

University, Fukuoka, Japan, 2Oregon Health & Science University, Portland, OR, 3Jagiellonian University, Cracow, Poland, 4Dermatology Clinic, Academic Health, Rzeszów, Poland, 5Ludwig-Maximilian University, Munich, Germany, 6Medical University of Warsaw, Poland, 7Chugai Pharmaceutical Co. Ltd., Tokyo, Japan, 8Kyoto University, Kyoto, Japan and 9Tokyo Teishin Hospital, Japan

15.40-15.50 Oral 074 [Poster 024] Psoriasis Stratification to Optimise Relevant Therapy (PSORT): Clinical and Demographic Predictors of Biologic Response for

Psoriasis RB Warren,1 D Burden,2 B Tomenson,4 M Soliman,4 R Emsley,4 CE Griffiths1 and CH Smith3 1Dermatology Centre, The University of

Manchester, Manchester, United Kingdom, 2University of Glasgow, Glasgow, United Kingdom, 3St John’s Institute of Dermatology, London, United Kingdom and 4Centre for Biostatistics, University of Manchester, Manchester, United Kingdom

15.50-16.00 Oral 075 [Poster 026] Hidradenitis Suppurativa Prevalence and Disease Associations Using the Clinical Practice Research Datalink JR Ingram,1 S Jenkins-Jones,2 D Knipe,3 C Morgan2 and V Piguet1 1Cardiff University, Cardiff, United Kingdom, 2Pharmatelligence,

Cardiff, United Kingdom and 3Bristol University, Bristol, United Kingdom

15.00-16.10 Oral 076 [Poster 057] Detection of High-risk Human Papillomavirus DNA in Cutaneous Squamous Cell Carcinoma Among Young Patients R Aoki, B Clanner-Engelshofen, B Feldner, L Birrou, T Ruzicka and M Reinholz Dermatology and Allergy, Ludwig-Maximilian-

University, Munich, Germany

15.10-16.20 Oral 077 [Poster 025] Neurofibromatosis Type 1 Related Breast Cancer: Increased Risk, Exceptional Histopathological Characteristics and Poor Survival S Peltonen,1 E Uusitalo,2 R Kallionpää,2 S Kurki,3 R Matti4 and J Peltonen2 1Dept. of Dermatol., Univ. of Turku and Turku Univ. Hosp.,

Turku, Finland, 2Dept. of Cell Biol. and Anatomy, Univ. of Turku, Turku, Finland, 3Auria Biobank, Univ. of Turku and Turku Univ. Hosp., Turku, Finland and 4Finnish Cancer Registry, Helsinki, Finland


Poster 272 Clinical Response and Impact on Auto-reactive B Cells in Uncontrolled Bullous Pemphigoid (BP) Patients Treated With Rituximab N Berkani1, S Calbo1, N Colliou1, F Caillot1, A Lim3, G Riou1, M Hertl2, P Musette1 and P Joly1 1Inserm U905, Institute for Research and

Innovation in Biomedicine, Rouen University Hospital, Rouen, France, 2Faculty of Medicine, Philipp University, Marburg, Germany and 3Antiviral Immunity, Biotherapy and Vaccine Unit, Institut Pasteur, Paris, France

Poster 437 Integrated Molecular and Morphological Characterization of Psoriasis Skin Provides Insights Into Disease Mechanisms U Wehkamp1, F Degenhardt2, E Rodrıguez1, H Baurecht1, N Volks1, F Thielking1, A Franke2 and S Weidinger1 1Department of

Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany and 2Institute of Clinical Molecular Biology, Christian-Albrechts-University, Kiel, Germany

44

Concurrent 9: Innate Inflammation and PsoriasisDate: Friday 9 September 2016Time: 15.00-16.30Room: Rotterdam

Chairs: Kilian Eyerich, Menno de Rie


15.00-15.10 Oral 078 [Poster 435] Autocrine IFN-k Maintains Baseline Type I Interferon Responses in Keratinocytes in a Tyk2 Dependent Manner M Sarkar,1 LC Tsoi,1 X Xing,1 L Yun,1 P Harms,1 J Stannard,2 JT Elder,1 S Getsios,3 JM Kahlenberg2 and JE Gudjonsson1 1Dermatology,

University of Michigan, Ann Arbor, MI, 2 Internal Medicine, University of Michigan, Ann Arbor, USA and 3Dermatology, Northwestern University, Chicago, USA

15.10-15.20 Oral 079 [Poster 243] CXCL17 Attenuates Imiquimod-induced Psoriasis-like Skin Inflammation by Recruiting Myeloid-derived Suppressor Cells and

Regulatory T Cells T Oka, M Sugaya, N Takahashi, T Takahashi, S Shibata, T Miyagaki, Y Asano and S Sato University of Tokyo, Tokyo, Japan

15.20-15.30 Oral 080 [Poster 400] A Novel and Accurate Animal Model of Psoriatic Dermatitis Induced by Epicutaneous Application of a p38 MAPK Activator in an

IL-17 Dependent Manner K Sakurai, T Dainichi, R Matsumoto, Y Nakano and K Kabashima Dermatology, Kyoto University Graduate School of Medicine, Japan

15.30-15.40 Oral 081 [Poster 377] IL-17E Favors the Recruitment of Neutrophils in Psoriasis via Macrophage Activation L Senra, R Stalder, W Boehncke and N Brembilla Department of Pathology and Immunology, University of Geneva, Switzerland

15.40-15.50 Oral 082 [Poster 432] ADAM17 is a Psoriasis-relevant Check-point Controlling Th17-programming by Inflammatory Dermal Dendritic Cells A Kunze,1 S Oehrl,1 P Beckhove,3 G Murphy,2 A Enk1 and K Schaekel1 1Dermatology, University Hospital, Heidelberg, Germany, 2

Oncology, University of Cambridge, Cambridge, United Kingdom and 3DKFZ, Heidelberg, Germany

15.50-16.00 Oral 083 [Poster 334] Role of RIP Kinase Signalling in the Development of Skin Inflammation in Mice With Keratinocyte-specific IKK Deficiency S Kumari, T Van and M Pasparakis Institute for Genetics, CECAD Research Center, Cologne, Germany

15.00-16.10 Oral 084 [Poster 284] HLA-C*06:02 Mediates an Autoimmune Response Against Melanocytes in Psoriasis A Arakawa,1 K Siewert,2 J Stöhr,1 P Besgen,1 S Vollmer,1 P Thomas,1 K Dornmair2 and JC Prinz1 1Dermatology, LMU, Münich,

Germany and 2 Clinical Neuroimmunology, LMU, Münich, Germany

15.10-16.20 Oral 085 [Poster 384] MicroRNA-146a Suppresses IL-17-mediated Skin Inflammation and Is Genetically Associated With Psoriasis A Srivastava, P Nikamo, W Lohcharoenkal, D Li, F Meisgen, N Landén, M Mona Ståhle, A Pivarcsi and E Sonkoly Dermatology and

Venerology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden


Poster 302 IL-17A Plays a Role in the Expression of Connective Tissue Growth Factor in a Newborn Mice Fibrosis Model Y Okamoto, T Matsushita, Y Hamaguchi and K Takehara Dermatology, Kanazawa University, Kanazawa, Japan

Poster 365 Activation of Resident T Cells in a Human Ex-vivo Model Induces Tissue Responses in Resolved Psoriasis I Gallais Sérézal, S Cheuk, D Chang and L Eidsmo Karolinska Institutet, SOLNA, Sweden

Poster 397 The TRPA1 Ion Channel Mediates Inhibitory Effects on Imiquimod-induced Psoriasiform Skin Inflammation A Kemény, S Horvath, R Komlodi, A Perkecz, C Gyömörei, E Pintér and R Gyulai University of Pécs, Pécs, Hungary

45

2016 René Touraine LectureGenetics, Immunology and Targeted Therapies in Alopecia AreataDate: Friday 9 September 2016Time: 17.45-18.15Room: Munich

Introduced by: Thomas Luger

Angela ChristianoRichard and Mildred Rhodebeck Professor of Dermatology and Professor of Genetics & Development Director, Basic Science Research Group of Dermatology, Columbia University Medical Center New York, USA

Dr Angelo Christiano’s major focus of research is the study of inherited skin and hair disorders in humans, through a classical genetic approach including identification and phenotyping of disease families, genetic linkage, gene discovery and mutation analysis, and most recently, functional studies relating these findings to basic questions in epidermal biology. Molecular aspects of the cutaneous basement membrane zone, adhesion junctions including hemidesmosomes and desmosomes, and epidermal appendages such as hair and teeth are major basic science interests in her laboratory. A long-range goal of the research is to develop rationally designed genetic therapies for skin and hair diseases through understanding the underlying pathogenetic mechanisms.


Dai Z, Xing L, Cerise J, Wang EH, Jabbari A, de Jong A, Petukhova L, Christiano AM, Clynes R. CXCR3 Blockade Inhibits T Cell Migration into the Skin and Prevents Development of Alopecia Areata. J Immunol. 2016 Aug 15;197(4):1089-99. doi: 10.4049/jimmunol.1501798. Epub 2016 Jul 13. PubMed PMID: 27412416.

Jabbari A, Cerise JE, Chen JC, Mackay-Wiggan J, Duvic M, Price V, Hordinsky M, Norris D, Clynes R, Christiano AM. Molecular signatures define alopecia areata subtypes and transcriptional biomarkers. EBioMedicine. 2016 May;7:240-7. doi: 10.1016/j.ebiom.2016.03.036. Epub 2016 Mar 31. PubMed PMID: 27322477; PubMed Central PMCID: PMC4909368.

Jabbari A, Nguyen N, Cerise JE, Ulerio G, de Jong A, Clynes R, Christiano AM, Mackay-Wiggan J. Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers. Exp Dermatol. 2016 Aug;25(8):642-3. doi: 10.1111/exd.13060. PubMed PMID: 27119625; PubMed Central PMCID: PMC4963264.

Petukhova L, Christiano AM. Functional Interpretation of Genome-Wide Association Study Evidence in Alopecia Areata. J Invest Dermatol. 2016 Jan;136(1):314-7. doi: 10.1038/JID.2015.402. PubMed PMID: 26763452; PubMed Central PMCID: PMC4870380.

Chen JC, Cerise JE, Jabbari A, Clynes R, Christiano AM. Master regulators of infiltrate recruitment in autoimmune disease identified through network-based molecular deconvolution. Cell Syst. 2015 Nov 25;1(5):326-337. PubMed PMID: 26665180; PubMed Central PMCID: PMC4670983.

Jabbari A, Dai Z, Xing L, Cerise JE, Ramot Y, Berkun Y, Sanchez GA, Goldbach-Mansky R, Christiano AM, Clynes R, Zlotogorski A. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib. EBioMedicine. 2015 Feb 26;2(4):351-5. doi: 10.1016/j.ebiom.2015.02.015. eCollection 2015 Apr. PubMed PMID: 26137574; PubMed Central PMCID: PMC4486197.

Betz RC, Petukhova L, Ripke S, Huang H, Menelaou A, Redler S, Becker T, Heilmann S, Yamany T, Duvic M, Hordinsky M, Norris D, Price VH, Mackay-Wiggan J, de Jong A, DeStefano GM, Moebus S, Böhm M, Blume-Peytavi U, Wolff H, Lutz G, Kruse R, Bian L, Amos CI, Lee A, Gregersen PK, Blaumeiser B, Altshuler D, Clynes R, de Bakker PI, Nöthen MM, Daly MJ, Christiano AM. Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nat Commun. 2015 Jan 22;6:5966. doi: 10.1038/ncomms6966. PubMed PMID: 25608926; PubMed Central PMCID: PMC4451186.

Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, de Jong A, Harel S, DeStefano GM, Rothman L, Singh P, Petukhova L, Mackay-Wiggan J, Christiano AM, Clynes R. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014 Sep;20(9):1043-9. doi: 10.1038/nm.3645. Epub 2014 Aug 17. PubMed PMID: 25129481; PubMed Central PMCID: PMC4362521.

Jabbari A, Petukhova L, Cabral RM, Clynes R, Christiano AM. Genetic basis of alopecia areata: a roadmap for translational research. Dermatol Clin. 2013 Jan;31(1):109-17. doi: 10.1016/j.det.2012.08.014. Epub 2012 Oct 23. Review. PubMed PMID: 23159180; PubMed Central PMCID: PMC4362526.

Petukhova L, Duvic M, Hordinsky M, Norris D, Price V, Shimomura Y, Kim H, Singh P, Lee A, Chen WV, Meyer KC, Paus R, Jahoda CA, Amos CI, Gregersen PK, Christiano AM. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature. 2010 Jul 1;466(7302):113-7. doi: 10.1038/nature09114. PubMed PMID: 20596022; PubMed Central PMCID: PMC2921172.

46

27– 30 September 2017Salzburg, Austria

www.esdr2017.org

The Sound of Dermatology

47th AnnualESDR–Meeting

47

SATURDAY

48

Frontiers in Skin Biology & Dermatology 2Date: Saturday 10 September 2016Time: 09.00-10.00Room: MunichChairs: Matthew Caley, Caterina Missero

Introduction

Dermatology has numerous interfaces with basic science fields. Thus, a constant update in these areas is crucial for the further development of dermatological research. The purpose of the Frontiers in Skin Biology and Dermatology lectures is to provide overviews about about emerging fields in science including non-dermatological topics that are relevant for experimental and clinical dermatology. These talks are principally intended as essential updates for “non-experts”. The Frontiers lectures are likely to be two of the most popular sessions at the 2016 ESDR meeting.

This ESDR educational session is supported by a grant from:

PROGRAM

09.00-09.30 Merlin Regulates Collective Migration of Epithelial Cells by Mechanobiology Joachim Spatz (Stuttgart, Germany)

09.30-10.00 Connecting Intestinal Stem Cells to Colorectal Cancer Eduard Batlle (Barcelona, Spain)

FACULTY

Joachim P. Spatz Joachim P. Spatz joined the Max Planck Institute for Metals Research (now Max Planck Institute for Intelligent Systems) as a Director

for the Dept. of New Materials and Biosystems in 2004. From this time on he is also a Full Professor at the University of Heidelberg and head of the Dept. of Biophysical Chemistry. He was an Associated Professor for Biophysical Chemistry at the University of Heidelberg from 2000-2004. From 1999-2000 he received his habilitation in Physics at the University of Ulm. He was a PostDoc with Prof. Albrecht Ott at the Institut Curie, Paris, in 1997 and 1998. He received his Diploma in Physics (1994) and his Ph.D. in Physics (1996) from the University of Ulm under the supervision of Prof. Martin Möller (DWI & RWTH Aachen).

Eduard Batlle Since 2004, working as a Research Professor at ICREA (Catalan Institute for Research and Advanced Studies) and Principal Investigator

and Programme Coordinator at the Oncology Programme at the Institute for Research in Biomedicine (IRB Barcelona).

1994-1999 PhD fellow at Institut Municipal de Investigació Mèdica (IMIM). 1993 BSc. Universitat de Barcelona. 1999: Associate professor in Biochemistry–Life Siciences at the University Pompeu Fabra, Barcelona. 1999-2000 PostDoctoral Fellow at Miguel Beato’s group, Institut für Molekularbiologie und Tumorforschung, Marburg. Germany. 2000-2004: PostDoctoral Fellow at Hans Clevers Lab, Netherlands Institute for Developmental Biology, Utrecht, NL.

Research activity in the last 10 years has focused on the characterization of the mechanisms that drive colorectal cancer initiation and progression. Among other findings, Eduard Batlle originally discovered the transcription factor Snail as a suppressor of E-cadherin expression in tumor cells and more recently the role of EphB receptors in colorectal cancer. His articles published in the last six years have been quoted more than 800 times and have received several reviews and comments in prestigious journals.

49

Plenary Session 2 Date: Saturday 10 September 2016Time: 10.00-11.00Room: Munich

Chairs: Michel Gilliet, Shinichi Sato, Mark Udey

Plenary talks are 8 minutes plus 2 minutes discussion.

10.00-10.10 Oral 009 [Poster 180] Mutations in FAM83G/PAWS1 cause Autosomal Recessive Palmoplantar Keratoderma with Leukonychia and Abundant Curly Hair T Maruthappu,1 L McGinty,1 D Blaydon,1 R Duit,2 A Maatta,2 E O’Toole1 and DP Kelsell1 1Cell Biology and Cutaneous Research, Blizard

Institute, QMUL, London, United Kingdom and 2School of Biological and Biomedical Sciences, Durham University, Durham, United Kingdom

10.10-10.20 Oral 010 [Poster 395] Lack of Type 2 Innate Lymphoid Cells Promotes a Type I Driven Enhanced Immune Response in TNCB Contact Hypersensitivity D Rafei-Shamsabadi,1 S Kunz,1 S Martin,1 C Klose,2 Y Tanriver,2 S Arnold,3 A Diefenbach,4 T Halim,5 A McKenzie5 and T Jakob6

1Department of Dermatology, Freiburg, Germany, 2Institute of Medical Microbiology, Freiburg, Germany, 3Institute of Experimental and Clinical Pharmacology and Toxicology, Freiburg, Germany, 4Institute of Medical Microbiology, Mainz, Germany, 5MRC, Laboratory of Molecular Biology, Cambridge, United Kingdom and 6Department of Dermatology and Allergy, Gießen, Germany

10.20-10.30 Oral 011 [Poster 550] MicroRNA-17-92 Promotes Wound Healing by Regulating Inflammatory Response in Keratinocytes D Li,1 X Li,1 E Herter,1 A Wang,3 A Pivarcsi,1 E Sonkoly,2 M Mona Ståhle2 and N Landén1 1Medicine, Karlolinska Institutet, Stockholm,

Sweden, 2Dermatology unit, Karolinska University Hospital, Stockholm, Sweden and 3Dalian Medical University, Dalian, China

10.30-10.40 Oral 012 [Poster 091] Epidermal Mineralocorticoid Receptor Plays Beneficial and Adverse Effects in Skin and Mediates Glucocorticoid Responses J Boix Tarín, L Sevilla, Z Sáez, E Carceller and P Pérez Animal Models of Skin Pathologies Unit, Instituto de Biomedicina de Valencia

(CSIC), Valencia, Spain

10.40-10.50 Oral 013 [Poster 220] TGFb Induces a SAMHD1-independent Post-Entry Restriction to HIV-1 Infection of Immature Langerhans Cells MA Czubala,1 K Finsterbusch,1 MO Ivory,1 SA Coulman,2 JC Birchall,2 FP Blanchet3 and V Piguet1 1Department of Dermatology,

Cardiff University - School of Medicine, Cardiff, United Kingdom, 2Cardiff University - School of Pharmacy and Pharmaceutical Sciences,Cardiff, United Kingdom and 3Centre d’études d’agents Pathogènes et Biotechnologies pour la Santé, Montpellier, France

NOTES................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................

50

2016 EADV Guest LectureClinical Implications of Genetic Discoveries in DermatologyDate: Saturday 10 September 2016Time: 11.00-11.30Room: Munich

Introduced by: Martin Röcken

Eli Sprecher, MD, PhDDirector, Department of Dermatology Tel Aviv Sourasky Medical Center Israel

Eli Sprecher’s large library of published research has merited worldwide recognition. His work has been honored with the Belgian Government

Prize (1981), the Rector’s Prize from the Hebrew University (1983), the Dean’s Prize from the Hebrew University (1983 - 1987), the Senta Foulkes Research Award (1994), the Tsipora Friedman Research Award (1998), the Israel Society of Dermatology Research Award, the Everett C. Fox Award from the American Academy of Dermatology (2002), the Bill Reed Award (2002), the Henry Taub Prize for Academic Excellence from Technion - Israel Institute of Technology (2006), and the Alfred Marchionini Award from the International Society of Dermatology (2007). Dr. Sprecher graduated with a B.Med. and M.D. in Medicine from the Hebrew University of Jerusalem, a Ph.D. in Molecular Virology from the Hebrew University of Jerusalem, and completed a fellowship program in Genetics of Skin Diseases at the Thomas Jefferson University of Philadelphia.


Sprecher E, Bergman R, Richard G, Lurie R, Shalev S, Petronius D, Shalata A, Anbinder Y, Leibu R, Perlman I, Cohen N, Szargel R. Hypotrichosis with juvenile macular dystrophy is caused by a mutation in CDH3 encoding P-cadherin. Nat Genet , Vol. 29 , pp. 134-136, 2001

Topaz O, Shurman DL, Bergman R, Indelman M, Ratajczak P, Mizrachi M, Khamaysi Z, Behar D, Petronius D, Friedman V, Zelikovic I, Raimer S, Metzker A, Richard G, Sprecher E. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet, Vol. 36, pp. 579-581, 2004

Israeli S, Khamaysi Z, Fuchs-Telem D, Nousbeck J, Bergman R, Sarig O, Sprecher E. A mutation in LIPN, encoding epidermal Lipase N, causes a late onset form of autosomal recessive congenital ichthyosis. Am J Hum Genet, Vol. 88, pp. 482-487, 2011

Nousbeck J, Burger B, Fuchs-Telem D, Pavlovsky M, Fenig S, Sarig O, Itin P, Sprecher E. A mutation in a skin-specific isoform of SMARCAD1 causes autosomal dominant adermatoglyphia. Am J Hum Genet, Vol 89, pp. 302–307, 2011

Fuchs-Telem D, Sarig O, van Steensel MAM, Isakov O, Israeli S, Nousbeck J, Richard K, Winnepenninckx V, Vernooij M, Shomron N, Uitto J, Fleckman P, Richard G, Sprecher E. Familial pityriasis rubra pilaris is caused by mutations in CARD14. Am J Hum Genet, Vol. 91, pp. 163-170, 2012

Sarig O, Nahum S, Rapaport D, Ishida-Yamamoto A, Fuchs-Telem D, Qiaoli Li, Cohen-Katsenelson K, Spiegel R, Nousbeck J, Israeli S, Borochowitz ZU, Padalon-Brauch G, Uitto J, Horowitz M, Shalev S, Sprecher E. Short stature-onychodysplasia-facial dysmorphism-hypotrichosis (SOFT) syndrome caused by a mutation in POC1A. Am J Hum Genet, Vol. 91, pp. :337-342, 2012

Eytan O, Morice-Picard F, Sarig O, Ezzedine K, Isakov O, Li Q, Ishida-Yamamoto A, Shomron N, Goldsmith T, Fuchs D, Adir N, Uitto J, Orlow SJ, Taieb A, Sprecher E. Cole disease results from mutations in ENPP1. Am J Hum Genet, Vol. 93, pp.752-757, 2013

Samuelov L, Sarig O, Harmon RM, Rapaport D, Ishida-Yamamoto A, Isakov O, Koetsier JL, Gat A, Goldberg I, Bergman R, Spiegel R, Eytan O, Geller S, Peleg S, Shomron N, Goh CSM, Wilson NJ, Smith FJD, Pohler E, Simpson MA, McLean WHM, Irvine AD, Horowitz M, McGrath JA, Green KJ, Sprecher E. Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and metabolic wasting. Nat Genet, Vol. 45, pp.1244-8, 2013

Eytan O, Fuchs-Telem D, Mevorach B, Indelman M, Bergman R, Sarig O, Goldberg I, Adir N, Sprecher E. Olmsted syndrome caused by a homozygous recessive mutation in TRPV3. J Invest Dermatol, Vol. 134, pp.1752-1754, 2014

Goldsmith T, Eytan O, Magal L, Solomon M, Israeli S, Warshauer E, Grafi-Cohen M, Aberdam D, van Bokhoven H, Zhou JH, Sarig O, Sprecher E, Nousbeck J. A novel mutation in TP63 causing a mild ectodermal dysplasia phenotype. J Invest Dermatol, Vol. 134, pp. 2277-2280, 2014

Nousbeck J, Sarig O, Magal L, Warshauer E, Burger B, Itin P, Sprecher E. Mutations in SMARCAD1 cause autosomal dominant adermatoglyphia and perturb the expression of epidermal differentiation-associated genes. Br J Dermatol, Vol. 171, pp. 1521-1524, 2014 Warshauer E, Samuelov L, Sarig O, Vodo D, Bindereif A, Kanaan M, Gat U, Fuchs-Telem D, Shomron N, Farberov L, Pasmanik-Chor M, Nardini G, Winkler E, Meilik B, Petit I, Paus R, Sprecher E, Nousbeck J. RBM28, a protein deficient in ANE syndrome, regulates hair follicle growth via miR-203 and p63. Exp Dermatol, Vol. 24, pp.618-22, 2015

Vodo D, Sarig O, Peled A, Frydman M, Greenberger S, Sprecher E. Autosomal dominant cutis laxa resulting from an intronic mutation in ELN. Exp Dermatol, in press, 2016

Tekin B, Yucelten D, Beleggia F, Sarig O, Sprecher E. Papillon–Lefèvre syndrome: Case series of 6 patients and identification of a novel mutation. Int J Dermatol, in press, 2016

Eskin-Schwartz M, Metzger Y, Peled A, Weissglas-Volkov D, Malchin N, Gat A, Vodo D, Mevorah B, Shomron N, Sprecher E, Sarig O. Somatic mosaicism for a “lethal” GJB2 mutation results in a patterned form of spiny hyperkeratosis without eccrine involvement. Ped Dermatol, in press, 2016

51

Clinical Saturday LecturesDate: Saturday 10 September 2016Time: 13.30-14.30Room: Munich

Chairs: Tilo Biedermann, Martin Röcken

About Clinical Saturday Lectures

The main mission of the ESDR is to foster basic research in dermatology and skin biology. To increase the exchange between basic scientists and clinicians at the annual meeting, the ESDR includes “Clinical Saturday Lectures” as part of the regular program. Dialogue and cross fertilization between these two groups is essential for the future prosperous development of dermatology. Clinical Saturday 2016 is run in association with the European Academy for Dermatology and Venereology (EADV).

PROGRAM

13.00-13.30 Bringing Genomic Medicine into the Clinic Vincent Mooser (Lausanne, Switzerland)

13.30-14.00 Towards Eradication of Herpes Zoster Sinead Langan (London, UK)

14.00-14.30 Combinatorial Treatments for Cutaneous Cancers Thomas Tüting (Magdeburg, Germany)

FACULTY

Vincent Mooser Vincent Mooser, MD is board certified in internal medicine and trained in clinical and experimental pharmacology and in molecular

genetics of lipid disorders. He joined CHUV/UNIL in 2011, after a 10-year position within GlaxoSmithKline R&D in Philadelphia. He co-founded the CoLaus study, and is the principal investigator of the Lausanne Institutional Biobank and the Swiss Biobanking Platform. Bringing the benefits of genomic sciences into the clinic requires a series of circular steps which all represent serious challenges : access to high quality data and samples from a large number of properly phenotyped consenting volunteers from the community, high-quality high-throughput sequencing and analytical laboratories, large bioinformatic and IT infrastructures to transform these large quantities of data into information and knowledge and, last but not least, demonstration of the clinical utility of this new knowledge and transformation into precision medicine to the benefits of the community. In his presentation, he plans to describe the initiatives that he has launched to close this cycle and bring genomic medicine into the clinic, with the implementation of a specific general consent, the creation of a large hospital-based biobank and the necessary IT infrastructures, linked to the clinical research center.

Sinead Langan Sinead Langan is Senior Lecturer and National Institute for Health Research Clinician Scientist at the London School of Hygiene &

Tropical Medicine, UK. Her research addresses three major areas: The epidemiology of skin diseases, reporting of observational research undertaken using routinely collected data and outcome measures research in eczema. In her recent research, she has established that the herpes zoster vaccine is very effective against herpes zoster and post-herpetic neuralgia in routine use in the general population in older individuals in the USA. This was the first study demonstrating effectiveness against post-herpetic neuralgia in routine use. These findings have great importance for countries currently considering introduction of the zoster vaccine into routine practice. Other zoster related work includes identfiying and highlighting to general practitioners the problem of under-prescription of antiviral therapy in the setting of acute herpes zoster, including amongst individuals at high risk of serious zoster-related complications, for example those with immunosuppression and complicated zoster.

Thomas Tüting Thomas Tüting, MD, is Professor and Chair of Dermatology at the University Hospital Magdeburg. He first trained in clinical

dermatology at the Army Hospital Koblenz and the University Hospital Mainz and subsequently in experimental tumor immunology at the University of Pittsburgh. In his former position as Associate Professor of Experimental Dermatology and Head of Dermato-Oncology in the Department of Dermatology at the University Hospital Bonn Dr. Tüting pioneered the establishment of novel genetic mouse model systems that combine experimental tools of tumor biology and tumor immunology to study the dynamic and reciprocal interactions between tumor and immune cells during disease progression and in response to therapeutic intervention. His laboratory has a long-standing interest in understanding the interplay between innate and adaptive immunity in the pathogenesis and treatment of melanoma, initially focussing on the role of type I IFNs for the regulation of T cell responses in the tumor microenvironment. Using adoptive T cell transfer approaches his group discovered that progressively growing autochthonous melanomas can resist cytotoxic T cell responses directed against melanocytic differentiation antigens through reversible dedifferentiation in an inflammatory microenvironment. His group also discovered that neutrophilic inflammatory responses in the skin induced by sunburning doses of UVB irradiation promote melanoma cell migration and metastatic dissemination. Current work addresses molecular and cellular mechanisms how inflammation shapes the heterogeneity and interdependent plasticity of melanoma and immune cells in tumor evolution and therapy resistance. A long-term goal is the preclinical and clinical development of more effective, patient-specific treatment protocols that combine complementary approaches of cancer therapy to re-establish and maintain immune surveillance.

52

PROGRAM

13.00-13.45 Horizon 2020: EU Funding Opportunities Greg Dow (QMUL, London)

13.45-14.00 Q & A

FACULTY Greg Dow Greg Dow has been working in EU funding since the beginning of FP7, when he worked for the UK Research Office (UKRO) in Brussels.

At UKRO, he advised UK universities on successful strategies for acquiring EU research funding, and also acted as National Contact Point for the UK for the European Research Council. Since leaving Brussels in 2009, Greg has worked for both the Liverpool and London School of Tropical Medicine, bringing in several successful EU grant proposals within Health research, including Marie-Curie fellowships, ERC grants, large scale cooperation programme grants and grants from other EU funders such as IMI and the European Agency for Health and Consumers. Since 2012, he has been working in the newly created EU Unit at Queen Mary University of London, where he focuses on advising academics in preparing successful proposals for Horizon 2020, setting up contracts and managing ongoing projects. He continues to work closely with UKRO and the network of National Contact Points to stay up to date with the latest developments in EU research funding.

Horizon 2020: EU Funding OpportunitiesDate: Saturday 10 September 2016Time: 13.00-14.00Room: Salzburg

Introduction

This ESDR Educational Session will look at funding available from the European Commission via the Horizon 2020 Programme, with a focus on fellowships and doctoral training programmes from the Marie Skłodowska-Curie Actions, including Individual Fellowships, Innovative Training Networks, Cofund and other European wide fellowship opportunities.

NOTES........................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................

53

Poster and Practical

Information

54

POSTER INFORMATION

Installation and Removal

• Printed posters must be installed on Thursday 8 September (poster areas open at 09.00). If you have used ESDR's poster printing service, please collect your poster from the registration desk.

• Please remove your poster by 17.00 on Saturday 10 September. Posters remaining after this time will be destroyed.

Poster Sessions

Two Poster Sessions are scheduled in addition to the general poster viewing session on Thursday 8 September

• POSTER SESSION I (ODD NUMBERS) Friday 9 September 2016, 11.30-13.00

All poster presenters of odd-numbered posters to stand in front of posters, except those joining poster walks (see below). Coffee will be available during this session.

• POSTER SESSION 2 (EVEN NUMBERS) Saturday 10 September 2016, 11.30-13.00 All poster presenters of even-numbered posters to stand in front of posters, except those joining poster walks (see next page). Coffee will be available during this session.

ELECTRONIC POSTER KIOSKS

All 2016 ESDR posters will be available for viewing throughout the meeting at Electronic Poster Kiosks. Twenty kiosks have been set up throughout the meeting venue. The Electronic Poster technology enables fast browsing/search and a facility to contact the author. A technician will be available to assist with any questions/problems. A venue floor plan showing the locations of the kiosks is on the last pages of this program book.

POSTER PRIZES

Several poster prizes will be awarded at the 2016 ESDR Meeting. The awards will be made at the closing ceremony on Saturday 10 September 2016.

55

POSTER WALKS

Poster walks will take place during poster viewing sessions from 11.30-12.30 on Friday 9 September and Saturday 10 September. The walks are thematic tours of selected electronic posters accompanied by a senior investigator. Each poster presenter will be asked to briefly describe their work and a short group discussion will be held. If your poster has been selected for a Poster Walk, please join the appropriate group at the relevant Electronic Poster Kiosk. See the venue map at the end of the program book.

Friday 9 September 2016

Topic Poster Kiosk Poster NumbersEpidermal Structure and Function 1 1 070, 085, 087, 090, 094, 103, 111, 117, 122, 127, 129Epidermal Structure and Function 2 2 066, 068, 086, 092, 093, 096, 097, 109, 123, 128, 133Inflammation, Immunity and Infection 1 3 230, 235, 245, 247, 255, 271, 300, 302, 365, 398Inflammation, Immunity and Infection 2 4 407, 408, 413, 418, 419, 420, 421, 437, 439, 443Inflammation, Immunity and Infection 3 5 370, 371, 379, 390, 399, 404, 406, 433, 438, 445, 446Inflammation, Immunity and Infection 4 6 259, 285, 292, 294, 306, 309, 314, 348, 350, 360Inflammation, Immunity and Infection 5 7 233, 237, 244, 280, 324, 373, 389, 429, 431, 441Clinical Outcomes 1 8 006, 018, 028, 036, 041, 043, 052, 054, 056, 058, 060, 061, 578Genetics and Cell Based Therapy 1 9 147, 150, 156, 160, 164, 166, 167, 170, 173, 177, 181, 189Melanoma and Other Skin Cancers 1 10 451, 455, 457, 465, 483, 486, 493, 498, 499, 506Melanoma and Other Skin Cancers 2 11 461, 464, 469, 474, 480, 482, 494, 495, 501, 510

Saturday 10 September 2016

Topic Poster Kiosk Poster NumbersEpidermal Structure and Function 3 1 065, 084, 088, 102, 119, 125, 130, 136, 138, 140Inflammation, Immunity and Infection 6 2 272, 278, 281, 318, 344, 354, 380, 397, 402, 405Inflammation, Immunity and Infection 7 3 223, 239, 252, 320, 333, 336, 367, 368, 372, 436Inflammation, Immunity and Infection 8 4 361, 382, 385, 391, 403, 409, 415, 426, 428, 430 Inflammation, Immunity and Infection 9 5 249, 253, 257, 258, 277, 310, 316, 346, 349, 357, 362 Photobiology and Pigmentation 6 512, 513, 514, 520, 523, 527, 532, 536, 537, 540, 541 Wound Healing and Tissue Remodelling 7 547, 551, 555, 560, 565, 570, 574, 577Clinical Outcomes 2 8 014, 015, 016, 017, 022, 023, 040, 047, 051, 053, 059, 063 Genetics and Cell Based Therapy 2 9 146, 155, 165, 174, 178, 183, 184, 187, 191Melanoma and Other Skin Cancers 3 10 452, 453, 459, 477, 478, 484, 489, 492, 497, 503Hair and Other Adnexal Structures 11 193, 205, 207, 208, 210, 211, 213, 214, 216, 217, 218

56

ESDR 2016 MEETING VENUE AND TRAVEL INFORMATIONESDR 2016 Meeting Venue

The 46th Annual ESDR Meeting in 2016 will be held at the Technical University of Munich, in Garching. Located in the north of Munich, the venue is easily reached from the city center as well as the airport. The University comprises 5 departments (Physics, Chemistry, Mechanical Engineering, Mathematics and Informatics) as well several important institutes including the Max Planck Institute for Astrophysics.

Technical University of Munich, Garching campus (TUM)Department of Mechanical EngineeringBoltzmannstr. 15D-85748 Garching bei Münchenhttp://www.tum.de/

How to get to the venue by public transportPublic transportation is included in the ESDR2016 meeting registration fee. Your name badge, which serves as a ticket, is valid for all public local transit of the MVV / MVG (S-Bahn, U-Bahn, tram, bus) in the season ticket rings 1 – 7 (Munich city area and trips from Munich city to/from Garching Forschungszentrum).

Please ensure to carry your name badge with you at any time when using public transportation.

For your first trip from the city center to Garching (before having collected your name badge) you will receive a registration confirmation by email just before the start of the ESDR meeting. In conjunction with your identity card or passport this registration confirmation entitles you to travel in the season ticket rings 1 – 7 (Munich city area and trip from Munich city to Garching Forschungszentrum) on the day of arrival using all Munich public transport as mentioned above.

Please note: When travelling from Munich airport you need a supplementary ticket, for example Single Day Ticket outer area for 6,40 Euros, to travel to the city center. From there on, your confirmation serves as a valid ticket.

From the city centerYou can reach the venue in approximately 20-30 minutes by underground depending on where you are travelling from in Munich. The underground line U6 departs every 10 minutes from the central stops ‘Sendlinger Tor’, ‘Marienplatz’ or ‘Odeonsplatz’. The meeting venue is located on the underground stop: Garching Forschungszentrum (U6 line). This is the final stop on the U6 line.

From Munich central stationTake the underground line U1 (direction ‘Mangfallplatz’) or U2 (direction ‘Messestand Ost’) to the station ‘Sendlinger Tor’, here change to the underground line U6 (direction ‘Garching Forschungszentrum’) to the final stop.

From Munich airportTake either the suburban train (S-Bahn) S1 (direction ‘Ostbahnhof‘) to the station ‘Neufahrn’ and change to the Bus 690 to ‘Garching Forschungszentrum’. The travelling time is approximately 30 minutes.

GENERAL INFORMATIONREGISTRATION DESK

The registration desk is located in the entrance area on the ground floor.

Opening HoursWednesday 7 September 08.30-18.30Thursday 8 September 07.15-19.00Friday 9 September 08.00-18.15Saturday 10 September 08.00-16.30

MEDIA CHECK

All speakers must take their presentations to the Media Check room on the ground floor ahead of their talks. Presenters are advised that they cannot connect their own computers in the meeting rooms.

Wednesday 7 September 11.30-18.00Thursday 8 September 07.30-21.00Friday 9 September 08.00-18.45Saturday 10 September 08.30-14.30

EXHIBITION

The exhibition is open to all registered ESDR delegates who have indicated on the registration form that they are “PRESCRIBERS”.

Thursday 8 September 10.00-17.00Friday 9 September 10.00-17.00Saturday 10 September 10.00-14.00

57

PRACTICAL INFORMATIONCertificate of AttendanceWill be given to attendees at the registration desk.

Credit CardsAll major credit cards are in general use in Germany. At the registration desk you can use Visa, Mastercard and American Express. Diners Club cards and Traveler Cheques cannot be accepted.

Duplication, Recording, PhotosPhotography, audio-taping, video-recording, or any other form of duplication is strictly prohibited in the session rooms and poster areas. Failure to comply with this rule could lead to your meeting credentials being removed.

Food & BeverageLunch is not served to delegates as part of the registration fee. A variety of meals and snacks can be purchased on campus.

InsuranceDelegates are advised to take out their own comprehensive travel insurance as the organizers shall not be liable for personal accidents, illness, losses or damage to private property.

InternetWifi at the venue is available free of charge.

LanguageThe official meeting language is English.

Meeting AppThe 2016 ESDR Meeting app is available for phones and tablets running IOS or Android. Once downloaded the app does not require an internet connection to function.

The meeting app contains all ESDR 2016 program information, general information and search functionality. You can also add events to customise your meeting program.

MembershipIf you wish to apply for membership of the ESDR, forms are available at the ESDR booth. For membership enquiries after the meeting, please contact the ESDR: [email protected]

Name BadgeIt is essential that you wear your name badge at all times while in the meeting venue and during the Social Events. Also carry your name badge at all times when using public transportation.

SmokingAll interior areas are non-smoking at the ESDR meeting venue. Smoking is permitted outside the main entrance. Please note that in Germany smoking is restricted in most public areas, including restaurants.

TaxiTaxi-München: +49 89 21 610 or +49 89 19 410IsarFunk Taxizentrale: +49 89-450 540

TippingService and VAT are included in the menu price in restaurants and bars. Still, it is typical to add 5-10%, generally ending with a full Euro amount. It is not typical to be given a check, then leave your money on the table. You have to tell the amount including tip you want to pay before you pay (via cash or credit card).

Services for ESDR 2016 delegatesRegistered delegates are entitled to the following services and material:• admission to all meeting sessions and to the welcome and closing ceremonies• abstract book, program book and meeting bag• coffee/tea/water

58

Year President Secretary Treasurer1971 F. Serri M. Prunieras R. Cormane1972 O. Braun-Falco M. Prunieras R. Cormane1973 S. Shuster M. Prunieras R. Cormane1974 H. Rorsman M. Prunieras R. Cormane1975 R. Cormane C. Lapière E. Christophers1976 K. Wolff C. Lapière E. Christophers1977 E. Jung C. Lapière E. Christophers1978 E. Christophers M. Greaves T. van Joost1979 R. Marks M. Greaves W. van Vloten1980 H. Schaefer M. Greaves W. van Vloten1981 E. Frenk M. Greaves W. van Vloten1982 M. Greaves H. Hönigsmann W. van Vloten1983 G. Plewig H. Hönigsmann W. van Vloten1984 W. van Vloten H. Hönigsmann B. Vermeer1985 A. Giannetti W.J. Cunliffe B. Vermeer1986 J.H. Saurat W.J. Cunliffe B. Vermeer1987 P. Fritsch W.J. Cunliffe B. Vermeer1988 W.J. Cunliffe G.L. Vejlsgaard R. Willemze1989 B. Vermeer G.L. Vejlsgaard R. Willemze1990 J. Ring G.L. Vejlsgaard R. Willemze1991 G.L. Vejlsgaard P.S. Friedmann R. Willemze1992 D.M. MacDonald P.S. Friedmann R. Willemze1993 G. Stingl P.S. Friedmann R. Willemze1994 P.S. Friedmann W. Sterry P. van de Kerkhof1995 T. Krieg W. Sterry P. van de Kerkhof

Year President Secretary-Treasurer

1996 W. Sterry P. van de Kerkhof1997 K. Thestrup-Pedersen P. van de Kerkhof 1998 R. Camp P. van de Kerkhof1999 P. van de Kerkhof L. Bruckner-Tuderman2000 I. Leigh L. Bruckner-Tuderman2001 G. Zambruno L. Bruckner-Tuderman2002 L. Bruckner-Tuderman L. French2003 J. Rees L. French2004 M. Röcken L. French2005 L. French M. Röcken2006 T. Schwarz M. Röcken2007 C. Pincelli M. Röcken2008 J. McGrath V. Piguet2009 R. Dummer V. Piguet2010 E. Healy V. Piguet2011 V. Piguet A. Enk2012 T. Biedermann A. Enk2013 A. Enk J. Barker2014 N. Reynolds J. Barker2015 M. Picardo J. Barker2016 J. Barker M. Gilliet

Executive Committee

PRESIDENTJ. Barker, London

SECRETARY-TREASURERM. Gilliet, Lausanne

PRESIDENT-ELECTM. Schmuth, Innsbruck

PAST-PRESIDENTM. Picardo, Rome

PAST OFFICERS OF THE ESDR BOARD

CURRENT ESDR EXECUTIVE COMMITTEE AND BOARD

Board Members

S. Aznar-Benitah, BarcelonaZ. Bata-Csörgõ, Szeged C. Griffiths, Manchester M. Hertl, MarburgA. Hovnanian, ParisD. Kelsell, LondonL. Larue, Paris C. Missero, NaplesS. Peltonen, TurkuM. de Rie, AmsterdamK. Steinbrink, Mainz T. Werfel, Hannover

59

The ESDR acknowledges the ongoing support from its Patron Members. Patron memberships help support ESDR members from Eastern Europe, the development of the JID and annual meeting-related projects.

Salvador Aznar-BenitahMartine BagotJonathan BarkerZsuzsanna Bata-CsorgoJohann W BauerDavid R BickersTilo BiedermannLeena Bruckner-TudermanAlexander EnkLars E FrenchPeter S FriedmannOlivier GaideMichel GillietChristopher E.M. GriffithsRussell P. HallEugene Healy

Alain HovnanianRoland KaufmannDavid KelsellThomas KriegBirgit LaneAntti LauermaLotus MallbrisLudovic MartinCornelia MauchDedee F MurrellMauro M. PicardoVincent PiguetCarlo PincelliGerd PlewigNicholas J ReynoldsLesley E Rhodes

Johannes RingMartin RoeckenMatthias SchmuthThomas SchwarzMona StahlePeter M SteijlenGeorg StinglAnna ThomasSandra TrompezinskiErwin TschachlerJouni UittoPeter CM van de KerkhofMaarten H VermeerJohn J Voorhees

Salvador Aznar-BenitahHervé BachelezJonathan BarkerTilo BiedermannAntonio CostanzoMenno De RieWim DeclercqGiovanni Di ZenzoBeate EckesHiva FassihiJudith FischerCarsten FlohrMarjan GarmynMichel Gilliet

Christopher GriffithsMuzz HaniffaMatthew HardmanCristina HasMichael HertlBernard HomeyAlain HovnanianDelphine JavelaudKim JensenMarcel JonkmanVeli-Matti KähäriYork KamenischDavid KelsellDavid Kelsell

Lionel LarueThierry MagnaldoJohn McGrathCaterina MisseroCatherin NiemannCarien NiessenTamar NijstenThierry PasseronRalf PausSirkku PeltonenMichael PhilpottVincent PiguetEhrhardt ProkschNick Reynolds

Matthias Schmuth Thomas SchwarzMichel SimonLone SkovEli SprecherKerstin SteinbrinkDes TobinMaarten VermeerThomas WerfelNorbert WikonkalAntony YoungChristina Zielinski

The ESDR acknowledges the great contributions of the following 2016 ESDR abstract reviewers who donated their time and efforts to peer-review this year‘s submissions:

ESDR PATRON MEMBERS

ESDR ABSTRACT REVIEWERS

2017 47th Annual ESDR Meeting Salzburg, Austria 27-30 September 2017

2018 International Investigative Dermatology Orlando, Florida 16-19 May 2018

2019 49th Annual ESDR Meeting Bordeaux, France 18-21 September 2019

FUTURE ESDR MEETINGS

60

41st JSIDThe 41st Annual Meeting of the Japanese Society for Investigative Dermatology

December 9(Fri.) - 11(Sun.) 2016

SENDAI INTERNATIONAL CENTER

Setsuya Aiba, M.D., Ph.D.Department of Dermatology,

Tohoku University Graduate School of Medicine

President

Venue

Dates

Mubanchi, Aobayama, Aoba-ku, Sendai 980-0856, Japan

1-1 Seiryo-cho, Aoba-ku, Sendai, 980-8574, Japan

Meeting Organizer :

Department of Dermatology,


Secretariat :

Kenshi YamasakiSecretary-General : The Japanese Dermatological Association

1-4, Hongo 4-chome, Bunkyo-ku, Tokyo 113-0033, Japan

Fax : +81-3-3812-6790

E-mail : [email protected] URL : http: // jsid41.jp/

Year ESDR Awards ESDR Honorary Members

2016 Jens-M Schröder (Germany), Giovanna Zambruno (Italy)

2015 Masayuki Amagai (Japan), Leena Bruckner-Tuderman (Germany)

2014 Robin Eady (UK), Wolfram Sterry (Germany)

2013 Ronald Marks (UK), Hiroshi Shimizu (Japan), Peter van de Kerkhof (Netherlands) 2012 Johannes Ring (Germany)

2011 Paul Bergstresser (USA), Koji Hashimoto (Japan), Anders Vahlquist (Sweden)

2010 Alberto Giannetti (Italy), Shinji Shimada (Japan)

2009 Ervin Epstein (USA), Peter Friedmann (UK)

2008 Kristian Thestrup-Pedersen (Denmark), William Cunliffe (UK)

2007 Thomas Krieg (Germany), John Stanley (USA)

2006 Rona MacKie (UK), Rein Willemze (Netherlands)

2003 Georg Stingl (Austria), Jouni Uitto (USA)

2000 J.P. Ortonne (France) M. Greaves (UK) J-H. Saurat (Switzerland) E. Macher (Germany) 1999 S. Jablonska (Poland), H. Ueki (Japan)

1998 T. Nishikawa (Japan), J. Voorhees (USA)1997 L. Juhlin (Sweden) 1996 O. Braun-Falco (Germany) W. van Vloten (Netherlands) J. Thivolet (France) E. Christophers (Germany) A. Giannetti (Italy) S. Katz (USA) D. McDonald (UK) S. Imamura (Japan)

Previously Awarded F. Serri (Italy), M. Prunieras (France) O. Braun-Falco (Germany), R. Cormane (Netherlands) R. Brun (Switzerland), A. Kint (Belgium) Ch. Lapière (Belgium), K. Mustakallio (Finland) H. Rorsman (Sweden), S. Shuster (UK) K. Wolff (Austria)

ESDR HONORARY MEMBERS AND AWARDS

61

41st JSIDThe 41st Annual Meeting of the Japanese Society for Investigative Dermatology

December 9(Fri.) - 11(Sun.) 2016

SENDAI INTERNATIONAL CENTER

Setsuya Aiba, M.D., Ph.D.Department of Dermatology,


President

Venue

Dates

Mubanchi, Aobayama, Aoba-ku, Sendai 980-0856, Japan

1-1 Seiryo-cho, Aoba-ku, Sendai, 980-8574, Japan

Meeting Organizer :

Department of Dermatology,


Secretariat :

Kenshi YamasakiSecretary-General : The Japanese Dermatological Association

1-4, Hongo 4-chome, Bunkyo-ku, Tokyo 113-0033, Japan

Fax : +81-3-3812-6790

E-mail : [email protected] URL : http: // jsid41.jp/

ESDR 2016: Exhibition Plan

Booth No. Exhibitor11 Roche Pharma AG12 Novartis Pharma GmbH13 Celgene International Sárl14 FibroTx15 European Society for Dermatological Research (ESDR)16 Biomimiq - a division of Aeon Astron Europe B.V.

Mainentrance

15

16

1411 12

13

Exhibition

Scienti�c Program

E-Poster Kiosk

PosterArea 1

Registration

EXHIBITION

The exhibition is open to all registered ESDR delegates who have indicated on the registration form that they are “PRESCRIBERS”.

Thursday 8 September 10.00-17.00Friday 9 September 10.00-17.00Saturday 10 September 10.00-14.00

ESDR 2016: Meeting Venue Plan

Main entrance

Munich2nd �oor

Media CheckGround �oor

CopenhagenGround �oor

RotterdamGround �oor

BordeauxGround �oor

ESDR O�ceGround �oor

Board Room1st �oor

Geneva2nd �oor

Edinburgh1st �oor

Salzburg1st �oor

PosterArea 2

PosterArea 1

Registration

PosterArea 3

PosterArea 4

PosterArea 6

PosterArea 5

Exhibition

Scienti�c Program

E-Poster Kiosk

\Mensa (5 min.) Voucher paymentCash payment

(5 - 10 min.)\

\

Poster walk 1

Poster walk 2

Poster walk 3

Poster walk 4

Poster walk 5

Poster walk 6

Snack barCash payment

Poster walk 7Poster walk 8

Poster walk 9

Poster walk 10

Poster walk 11

DEIXE

00055

Marketing Authorisation Holder: Eli Lilly Nederland B.V.; Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands; local representative in Germany: Lilly Deutschland GmbH, Werner-Reimers-Str. 2-4, D-61352 Bad Homburg. Name of the medicinal product: Taltz® 80 mg solution for injection in pre-filled pen / in pre-filled syringe. Composition: active substance: Each pre-filled pen/syringe contains 80mg ixekizumab in 1 ml solution Excipients: Sodium citrate; citric acid, anhydrous; sodium chloride; polysorbate 80; water for injections. Therapeutic indications: Indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Contraindications: Serious hypersensitivity to the active substance or to any of the excipients. Clinically important active infections (e.g. active tuberculosis). Side effects: Taltz should be discontinued immediately and a physician should be contacted in case of the following side effects: Possible serious infection (≤ 1 in 100 people) – the signs may include: fever, flu-like symptoms, night sweats, feeling tired or short of breath, cough which will not go away, warm, red and painful skin, or a painful skin rash with blisters. Serious allergic reaction (frequency cannot be estimated from the available data) - the signs may include: difficulty breathing or swallowing, swelling of the face, lips, tongue or throat, severe itching of the skin, with a red rash or raised bumps. Other side effects: Very common (>1 in 10 people): upper respiratory tract infections with symptoms such as sore throat and stuffy nose (nasopharyngitis); injection site reactions (e.g. red skin, pain). Common (≤ 1 in 10 people): nausea (feeling sick); tinea (fungal) infections such as athlete’s foot; pain in the back of the throat. Uncommon (≤ 1 in 100 people): oral thrush (oral candidiasis); influenza; runny nose; bacterial skin infection; hives; discharge from the eye with itching, redness and swelling (conjunctivitis); signs of low levels of white blood cells, such as fever, sore throat or mouth ulcers due to infections (neutropenia); low blood platelet count (thrombocytopenia). Keep out of the sight and reach of children. If seal is broken, do not use. Do not shake. Subject to medical prescription.

* PASI 75: 90%; PASI 90: 71%; PASI 100: 41%1 1 Griffiths CEM, et al. Lancet. 2015; 386(9993):541-551 (UNCOVER 2)

Available

in Germany

in spring 2017

GET MANY OF

YOUR PATIENTSCLEAR* FROM

PSORIASIS**

CLEAR.* TOUCHABLE.SKIN.

NOW APPROVED!

**Taltz is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

46TH ANNUAL ESDR MEETING - Home page | ESDR …esdr2016.org/pdf/2016ESDRProgramBook.pdf · TABLE OF...

Documents

Transcript of 46TH ANNUAL ESDR MEETING - Home page | ESDR …esdr2016.org/pdf/2016ESDRProgramBook.pdf · TABLE OF...